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Abstract 
Background: The nitration of tyrosine residues in proteins is associated with nitrosative 
stress, resulting in the formation of 3-nitrotyrosine (3-NT). 3-NT levels in biological samples 
have been associated with numerous physiological and pathological conditions. For this 
reason, several attempts have been made in order to develop methods that accurately 
quantify 3-NT in biological samples. Regarding chromatographic methods, they seem to be 
very accurate, showing very good sensibility and specificity. However, accurate 
quantification of this molecule, which is present at very low concentrations both at 
physiological and pathological states, is always a complex task and a target of intense 
research.   
Objectives: We aimed to develop a simple, rapid, low-cost and sensitive 3-NT quantification 
method for use in medical laboratories as an additional tool for diagnosis and/or treatment 
monitoring of a wide range of pathologies. We also aimed to evaluate the performance of 
the HPLC-based method developed here in a wide range of biological matrices. 
Material and methods: All experiments were performed on a Hitachi LaChrom Elite® 
HPLC system and separation was carried out using a Lichrocart® 250-4 Lichrospher 100 
RP-18 (5µm) column. The method was further validated according to ICH guidelines. The 
biological matrices tested were serum, whole blood, urine, B16 F-10 melanoma cell line, 
growth medium conditioned with the same cell line, bacterial and yeast suspensions. 
Results: From all the protocols tested, the best results were obtained using 0.5% 
CH3COOH:MeOH:H2O (15:15:70) as the mobile phase, with detection at wavelengths 215, 
276 and 356 nm, at 25ºC, and using a flow rate of 1 mL/min. By using this protocol, it was 
possible to obtain a linear calibration curve (correlation coefficient = 1), limits of detection 
and quantification in the order of ng/mL, and a short analysis time (<15 minutes per sample). 
Additionally, the developed protocol allowed the successful detection and quantification of 
3-NT in all biological matrices tested, with detection at 356 nm.   
Conclusion: The method described in this study, which was successfully developed and 
validated for 3-NT quantification, is simple, cheap and fast, rendering it suitable for analysis 
in a wide range of biological matrices. 
Keywords: 3-nitrotyrosine, nitrosative stress, HPLC-DAD, quantification methods
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Resumo 
Introdução: A nitração de resíduos de tirosina em proteínas está associada ao stress 
nitrosativo, resultando na formação de 3-nitrotirosina (3-NT). Os níveis de 3-NT em 
amostras biológica têm sido associadas com numerosas condições fisiológicas e patológicas. 
Por esta razão, várias tentativas têm sido levadas a cabo no sentido de desenvolver métodos 
que quantifiquem 3-NT com precisão em amostras biológicas. Relativamente aos métodos 
cromatográficos, exibem, em geral, boa precisão, sensibilidade e especificidade. Contudo, a 
quantificação exata desta molécula, que está presente em concentrações muito baixas, tanto 
em condições fisiológicas como em patológicas, continua a ser uma tarefa complexa e alvo 
de investigação. 
Objetivos: Pretendeu-se desenvolver um método de quantificação de 3-NT rápido, 
económico, simples e sensível, para uso em laboratórios médicos como ferramenta adicional 
de diagnóstico e/ou monitorização do tratamento de diversas patologias. Pretendeu-se 
igualmente avaliar o desempenho do método desenvolvido numa variedade de matrizes 
biológicas.  
Material e métodos: As experiências foram realizadas no sistema HPLC Hitachi LaChrom 
Elite®, com separação na coluna RP-18 Lichrospher LiChroCART® 250-4 100 (5 um). O 
método foi validado de acordo com as diretrizes da ICH. As matrizes biológicas testadas 
foram soro, sangue total, urina, linha celular de melanoma B16 F-10, meio de crescimento 
condicionado com a mesma linha de celular, suspensões bacterianas e de levedura. 
Resultado: De todos os protocolos testados, os melhores resultados foram obtidos utilizando 
0.5% CH3COOH:MeOH (15:15:70) como fase móvel, com deteção a 215, 276 e 356 nm, a 
25ºC, e uma taxa defluxo de 1 mL/min. Utilizando este protocolo, foi possível obter curva 
de calibração linear (coeficiente de correlação = 1), limites de deteção equantificação na 
ordem dos ng/mL, e um tempo de análise reduido (<15 minutos por amostra). 
Adicionalmente, o protocolo desenvolvido permitiu a deteção e quantificação de 3.NT em 
todas as matrizes biológicas testadas, com deteção a 356 nm. 
Conclusão: O método descrito, que foi desenvolvido e validado com sucesso para 
quantificação de 3-NT, é simples, barato e rápido, tornando-o apropriado para análise de 
uma grande diversidade de matrizes biológicas. 
Palavras-chave: 3-nitrotirosina, stress nitrosativo, HPLC-DAD, métodos de quantificação 
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1.1. Biological markers of oxidative stress 
Oxidative stress is defined as an imbalance of antioxidants and pro-oxidants in favour of the 
latter, potentially leading to damage (de M Bandeira et al., 2013; Jones, 2006). On the other 
hand, Jones (2006) defines oxidative stress as a disruption of redox signalling and/or control 
of molecular damage. The reactive oxygen species (ROS) and reactive-nitrogen species 
(RNS) have function in redox signalling and are produced as by-products of normal 
metabolic process in all aerobic organisms, at very low concentrations in cells (Jones, 2006; 
Ogino & Wang, 2007). Increased oxidative/nitrosative stress is characterized by inadequate 
cellular antioxidant defences to efficiently inactivate the overproduced ROS and RNS. A 
major consequence of oxidative/nitrosative stress is the damage of nucleic acid bases, 
proteins, lipids (including phospholipids) and carbohydrates (Dalle-Donne, Rossi, Colombo, 
Giustarini, & Milzani, 2006; Ogino & Wang, 2007). This damage can compromise cell 
health and viability, as well as induce a variety of cellular responses like cell death by 
necrosis or apoptosis (Dalle-Donne et al., 2006).  
The molecules modified by interactions with ROS (including RNS) in the 
microenvironment, and those changed in response to increased redox stress are considered 
biomarkers of oxidative stress (Ho et al., 2013). Figure 1 represents a schematization of 
biomarkers of oxidative stress.  
A very promising approach for the assessment of oxidative stress is the detection of nitrated 
tyrosine (Tyr) residues in proteins (Safinowski et al., 2009). 
1.2. Nitrotyrosine in physiological conditions  
Tyr (4-hydroxyphenylalanine) is a non-essential amino acid and an element of the aromatic 
amino acids group. Most proteins found in nature contain Tyr residues in their composition, 
with an average abundance of about 3–4 mol % (Ahsan, 2013; Radi, 2013b). Tyr is 
moderately hydrophilic, which is explained by its hydrophobic aromatic benzene ring 
carrying a hydroxyl group (Bartesaghi et al., 2007; Ryberg & Caidahl, 2007). As a result, 
Tyr is frequently surface-exposed in proteins allowing further modification, namely 
nitration. The nitration of Tyr residues in proteins is associated with nitrosative stress, 
resulting in the formation of 3-nitrotyrosine (3-NT) or other Tyr-nitrated proteins residues 
(Ahsan, 2013; Tsikas, 2012).  
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When RNS reacts with L-tyrosine and protein-associated Tyr, free 3-nitro-L-tyrosine and 
protein-associated 3-nitro-L-tyrosine are formed (Figure 2) (Tsikas & Caidahl, 2005). 3-NT 
[(2-amino-3-(4-hydroxy-3-nitrophenyl) propanoic acid)] is the result of a post-translational 
modification in proteins carried by RNS, such as nitric oxide (NO), derived oxidants (e.g., 
peroxynitrite (ONOO-) and peroxynitrous acid (ONOOH)) and nitrogen dioxide radicals 
(•NO2). It is formed after the substitution of a hydrogen by a nitro group (NO2) in the ortho 
position of the phenolic ring of the Tyr residues (Ahsan, 2013; Radi, 2013b; Ryberg & 
Caidahl, 2007; Tsikas, 2012). 
The protein tyrosine nitration (PTN) is a stable post-translational modification process and 
does not happen randomly. The abundance of protein or Tyr residues cannot predict whether 
Figure 1. Formation pathways of selected biomarkers of oxidative stress. 
Oxidized Low-Density Lipoprotein (Ox-LDL). Protein oxidation markers: protein nitration (3-nitrotyrosine). 
Oxidative DNA damage biomarkers: 8-hydroxy-2′-deoxyguanosine (8-OHdG). Antioxidant enzymes and 
molecules: superoxide dismutase, catalase, glutathione peroxidase, oxidized glutathione, total antioxidant 
capacity. GS, glutathione; reduced glutathione (GSH); oxidized glutathione (GSSG); PUFA, polyunsaturated 
fatty acids. Nicotinamide adenine dinucleotide phosphate (NADPH), nitric oxide synthase (NOS), 
mieloperoxidase (MPO). Adapetd from (Ho, Karimi Galougahi, Liu, Bhindi, & Figtree, 2013) and (Shah, 
Mahajan, Sah, Nath, & Paudyal, 2014). 
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they will be the target of PTN. Furthermore, not all Tyr residues in a protein are available 
for nitration, which may depend on their accessibility to the solvent (Ahsan, 2013; Seeley, 
Fertig, Dufresne, Pinho, & Stevens, 2014). For instance, although the human serum albumin 
(HSA), a protein most abundantly found in plasma, contains 18 Tyr residues, an in vitro 
study showed that only two of its Tyr residues are predominantly susceptible to nitration 
(Jiao, Mandapati, Skipper, Tannenbaum, & Wishnok, 2001; Tsikas, 2012). 
The wide range of chemical and structural modifications of proteins, such as modifications 
affecting signal transduction pathways and cellular processes, are responsible for high levels 
of RNS and antioxidant enzymatic systems (Larsen, Bache, Gramsbergen, & Roepstorff, 
2011; Yeo, Lee, Lee, & Kim, 2008).  
 
 
 
 
Figure 2. Nitration of L-tyrosine to 3-nitro-L-tyrosine (Adapted fromTsikas and Caidahl (2005). 
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1.3. Metabolism of nitric oxide and its role in 3-nitrotyrosine biosynthesis 
The major pathway for NO metabolism is the stepwise oxidation to nitrite and nitrate (Bryan 
& Grisham, 2007). In biological fluids or buffers, NO systems are almost completely 
oxidised to nitrite (NO2
-), a biologically inert metabolite of NO oxidation (Shiva, 2013).  
The oxidation of NO by molecular oxygen (O2), physically dissolved in biological systems, 
originates NO2 (nitrogen dioxide), N2O3 (dinitrogen trioxide) and NO2
- (reactions 1, 2 and 
3). N2O3 is characterised as a potent nitrosating agent, since it gives rise to the formation of 
the nitrosonium ion (NO+). On the other hand, NO and NO2
- are rapidly oxidised to nitrate 
(NO3
-) in blood (Bryan & Grisham, 2007; Tsikas, 2012).  
 
2 NO + O2 → 2 NO2 (1)  
2 NO + 2 NO2 → 2 N2O3 (2)  
2 N2O3 + 2 H2O→ 4 NO2– + 4 H+ (3)  
  
In erythrocytes, NO directly and rapidly reacts with O2 bound to haemoglobin (i.e. 
oxyhemoglobin (Hb[Fe2+]O2 )), to form the chemically quite inert anion NO3
- (reaction 4). 
 
Hb[Fe2+]O2 + NO → Hb[Fe3+] + NO3- (4)  
 
Other proposed mechanism for NO3
- formation is via oxidation of NO2
- (derived from NO 
autoxidation – reaction 3) by certain oxyhemoproteins (Hb[Fe2+]O2), such as oxyhemoglobin 
or oxymyoglobin (reactions 5 and 6). 
  
2 Hb[Fe2+]O2 + O2 + 3 NO2
- + 2 H+ → Hb[Fe3+]+ 3 NO3- + H2O (5)  
4 Hb[Fe2+]O2 + 4 NO2
– + 4 H+ → 4 Hb[Fe3+]O2 + 4 NO3– + O2 + 2 H2O (6)  
 
Concerning free radical superoxide (O2
–), this may promptly interact with NO to produce 
the peroxynitrite anion (ONOO–) (reaction 7) (Radi, 2004; Surmeli, Litterman, Miller, & 
Groves, 2010).  
 
NO + O2
-→ ONOO- (7)  
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Peroxynitrite is the extremely reactive conjugate base of peroxynitrous acid (ONOOH) 
(reaction 8) (Bryan & Grisham, 2007; Tsikas, 2012).  
 
4 ONOO-+ 4 H+ ↔ 4 ONOOH → 2 NO3- + 2 NO2- + O2 + 4 H+ (8)  
 
In biological systems, ONOO-/ONOOH system is a very strong oxidant and a potent 
nitrating agent, thus it has been implicated as a culprit in many diseases (Goldstein & 
Merényi, 2008). Peroxynitrite promotes nitration and hydroxylation in different bioorganic 
molecules, including proteins, lipids, thiols, sulfhydryl groups, DNA bases, and 
preferentially nitrates Tyr residues of protein or non-protein origins (Bircan, Balabanli, 
Turkozkan, & Ozan, 2011; Radi, 2013a). Peroxynitrite reacts with CO2 to yield a 
nitrosoperoxycarbonate anion (ONOOCO2
−) that undergoes a fast homolysis to NO2 and 
carbonate radicals (CO3
−) (reaction 9) (Kikugawa, Hiramoto, & Ohkawa, 2004; Radi, 2013a; 
Yeo et al., 2008). 
 
ONOO–+ CO2 → ONOOCO2–→ •NO2 + CO3• – (9)  
 
The in vivo production of ONOO− leads to the nitration of Tyr residues in proteins, forming 
3-NT, although it does not directly react with Tyr. Instead, it forms secondary radicals, such 
as CO3
•–, •NO2 and oxo-metal complexes, which are indeed responsible for protein Tyr 
oxidation and nitration. The mechanism of Tyr nitration in biological systems is a two-step 
process (reactions 10 and 11) (Radi, 2013a). 
 
TyrH + CO3
• – →Tyr• + HCO3− (10)  
Tyr• + •NO2  → Tyr-NO2 (11)  
 
Moreover, 3-NT may be generated through multiple pathways (Figure 3). Tyr can be nitrated 
by peroxidase (or heme/hemoprotein) through the in vivo hydrogen peroxide-dependent 
oxidation of nitrite to form NO2 (reactions 12-14) (Bryan & Grisham, 2007; Sun et al., 2007; 
Yeo et al., 2008).  
 
H2O2 + peroxidase (heme) → oxidant (porphyrin radical) (12)  
Oxidant + NO2- → •NO2 (13)  
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2 •NO2  + Try → 3-NT (14)  
 
  
 
1.4. Association between 3-nitrotyrosine and disease 
Several physiological and pathological conditions have been associated with increased 
nitration of proteins (Seeley et al., 2014; Surmeli et al., 2010). Among the pathological 
conditions, there is a wide range of cardiovascular diseases, such as myocardial 
inflammation, heart failure and arteriosclerosis (Daiber & Münzel, 2012; de M Bandeira et 
al., 2013; Kagota et al., 2010; Nuriel, Deeb, Hajjar, & Gross, 2008; Yakovlev & Mikkelsen, 
2010). For instance, Shishehbor et al. (2003) and Poufarzam et al. (2013) demonstrated that 
3-NT plasma levels are elevated in coronary artery disease (CAD) patients. Regarding 
atherosclerosis, it was found that atherosclerotic arteries have higher 3-NT levels than non-
atherosclerotic blood vessels (Sucu et al., 2003). Furthermore, there is also evidence of an 
accumulation of 3-NT during atherogenesis (Upmacis, 2008). 
Figure 3. Multiple pathways for the formation of 3-nitrotyrosine (Adapted from (Bryan & 
Grisham, 2007)). 
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In addition, diseases associated with immunological reactions appear to be connected at a 
very high degree with the increased formation of Tyr-nitrated proteins, such as asthma 
(Voraphani, Gladwin, Trudeau, & Wenzel, 2013), systemic sclerosis (Shimizu et al., 2007), 
renal complications (Shah et al., 2014), inflammatory bowel disease (Kruidenier, Kuiper, 
Lamers, & Verspaget, 2003), septic shock (Teng et al., 2011), rheumatoid arthritis and joint 
injury (Misko et al., 2013; Winyard et al., 2011). In relation to asthma, 3-NT expression was 
found to be increased in several asthmatic epithelial cells and essentially in asthmatic 
children (Baraldi et al., 2006; Voraphani et al., 2013). Concerning systemic sclerosis, 
Shimizu et al. (2007) suggested that serum 3-NT levels are significantly increased in 
systemic sclerosis patients compared to healthy controls. Regarding inflammatory bowel 
diseases, such as ulcerative colitis, the 3-NT expression is substantially increased in the 
inflamed colonic mucosa (Kruidenier et al., 2003). Furthermore, some neurological diseases 
and psychiatric disorders are also associated with an increased level of nitrated proteins. For 
example, Parakh et al. (2013) reported that nitrated proteins and high levels of 3-NT have 
been detected in cases of amyotrophic lateral sclerosis. Conversely, Mendonça et al. (2011) 
demonstrated that 3-NT was expressed in both amyotrophic lateral sclerosis and control 
samples, with no significant difference between them. Moreover, Dietrich-Muszalska et al. 
(2009) considered that the amount of 3-NT in plasma proteins may be important indicators 
of in vivo protein damage in schizophrenia. Besides, high levels of 3-NT have also been 
associated with other pathological conditions, such as Alzheimer’s disease (Mangialasche et 
al., 2009), Parkinson’s disease (Blanchard-Fillion et al., 2006), autism (Rose et al., 2012) 
and myalgic encephalomyelitis/ chronic fatigue syndrome (Morris & Maes, 2014).  
Other diseases are associated with increased protein nitration. Shu et al. (2014) demonstrated 
that 3-NT levels in plasma samples from patients with classical Fabry disease were about 
six-fold higher compared with age- and gender-matched controls. The 3-NT levels are also 
significantly increased in diabetic patients (de M Bandeira et al., 2013; Jialal, Devaraj, 
Adams-Huet, Chen, & Kaur, 2012), especially in patients with diabetic nephropathy 
(Thuraisingham, Nott, Dodd, & Yaqoob, 2000) or diabetic patients with microvascular 
complications (Devaraj et al., 2007). Regarding Chagas disease, Dhiman et al. (2008) 
considered that 3-NT-modified proteins is an important phase in the pathophysiology of such 
disease, and might be useful biomarkers of disease as well. Moreover, Shah et al. (2014) 
demonstrated that 3-NT levels were increased in plasma and serum of patients with systemic 
lupus erythematosus.  
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1.5. Quantification of 3-nitrotyrosine in biological samples 
Since 3-NT was suggested as a biomarker of nitrosative stress, a substantial effort has been 
made to develop analytical methods that can be applied to biological samples (Guvenç, 
Aksoy, Kursad, Atmaca, & Yavuz, 2014). Accurate quantification of substances present in 
biological samples at very low concentrations is, indeed, a complex task, and the particular 
case of 3-NT requires special concerns (Tsikas & Caidahl, 2005).  
3-NT has been detected in several biological tissues and fluids including plasma, serum, 
urine, cerebrospinal fluid, synovial fluid, tissue samples and other biological samples 
(Radabaugh, Nemirovskiy, Misko, Aggarwal, & Mathews, 2008). Recently, Mergola et al. 
(2013) developed for the first time the synthesis of a highly selective molecularly imprinted 
polymer (MIP) used as solid-phase extraction (SPE) sorbent for pre-concentration of 3-NT 
and the selective clean-up from biological sample. The results obtained suggest that this 
polymer can be used as an active site in a sensor so that the analyte can be directly identified 
in the urine of patients, where it is normally present at very low concentrations.  
Regarding quantification of 3-NT, the first approaches used different immunological 
methods. In fact, a large part of studies on quantification of 3-NT in biological samples has 
been performed using antibody-based methods, namely immunohistochemistry and western 
blot (Ryberg & Caidahl, 2007).  
1.5.1. Immunochemical methods 
1.5.1.1. Enzyme-linked immunosorbent assay  
ELISA (enzyme-linked immunosorbent assay) is based on the basic immunology concept of 
the binding properties of an antibody to its specific antigen. From a general point of view, 
this method employs enzyme-labelled antigens and antibodies to detect a wide variety of 
compounds. The antigen-antibody complex is further bound by a secondary enzyme-coupled 
antibody, followed by the addition of a chromogenic substrate which yields a visible colour 
change or fluorescence, allowing the quantification of the compound (Gan & Patel, 2013). 
One of the main advantages of ELISA technology is that it allows the simultaneous 
determination of standards and samples. Moreover, it does not require complex sample 
preparation steps (Gan & Patel, 2013). 
Regarding 3-NT quantification, there is a wide variety of ELISA-based methods for this 
purpose, namely indirect, competitive, sandwich-ELISA and ELISA microarrays (Jin & 
Biomarkers of Nitrosative Stress: 
Development and validation of a new analytical method for 3-Nitrotyrosine quantification 
   10 
  
Zangar, 2012; Weber et al., 2012). Table I lists some ELISA assays for the analysis of 3-NT 
in different biological specimens.  
 
 
One of the first ELISA methods for the analysis of nitrated proteins in biological fluids was 
based upon a competitive model (J. Khan et al., 1998). More recently, Safinowski et al. 
Table I. ELISA assays for the analysis of 3-NT in different biological specimens 
Compound  Biological specimen ELISA Type Reference 
3-NT Bronchoalveolar lavage Sandwich ELISA 
(Fitzpatrick, Brown, 
Holguin, & Teague, 2009) 
3-NT-containing 
proteins 
Plasma Competitive ELISA 
(Dietrich-Muszalska et al., 
2012) 
3-NT-modifed 
proteins 
Plasma Competitive ELISA (J. Khan et al., 1998) 
3-NT Plasma and serum 
Competitive luminescence 
assay (CLIA) 
(Safinowski et al., 2009) 
3-NT Plasma Solid phase ELISA (Safinowski et al., 2009) 
3-NT Plasma and serum Sandwich ELISA (Sun et al., 2007) 
3-NT Plasma and sputum ELISA microarray (Jin & Zangar, 2012) 
3-NT Plasma Sandwich ELISA (Jialal et al., 2012) 
3-NT Serum Sandwich ELISA (Shimizu et al., 2007) 
Protein bound  
3-NT 
Serum Sandwich ELISA 
(F. Khan, Siddiqui, & Ali, 
2006) 
Protein bound  
3-NT 
Plasma and serum Indirect ELISA (Weber et al., 2012) 
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(2009) performed a comparison of the performance of different commercially available 
immunoassays for 3-NT analysis, and concluded that all of them did not provide reliable 
results. They also concluded that the sandwich-based ELISA assay exhibited the worst 
performance, probably due to the low concentration levels of 3-NT in almost all investigated 
samples. ELISA requires at least two 3-NT residues for the capture and detection antibody 
and, in this sense, the sandwich ELISA measures only protein associated-3-NT (Safinowski 
et al., 2009; Sun et al., 2007; Weber et al., 2012). Actually, the poor performances exhibited 
by different ELISA can be due to different reasons: (i) the antibodies may reveal some 
nonspecific binding; (ii) 3-NT may not be totally accessible to the antibody in some protein 
sites; and (iii) monoclonal and polyclonal antibodies used by these methods may exhibit 
cross-reactivity with other compounds present in biological samples (Sodum, Akerkar, & 
Fiala, 2000).  
Regarding microarray-ELISA assays, one of their main advantages is that they use various 
physically separated capture antibodies (in isolated spots), allowing an efficient way for 
measuring low levels of the analyte (Jin & Zangar, 2012). 
1.5.2. Chromatographic methods 
Chromatography is a powerful analytical technique, and is widely available in different 
laboratory settings nowadays. Chromatography is a technique for separation of complex 
mixtures and was described at the beginning of the twentieth century by Russian–Italian 
botanist M. S. Tswett (Wixom & Gehrke, 2011). This technique is generally composed by 
two primary components: mobile phase and stationary phase (Naushad & Khan, 2014). 
Table II shows chromatography classifications according to the mobile and stationary phases 
used.  
Table II. Chromatographic techniques used based on samples characteristics 
Chromatographic 
technique 
Mobile 
phase 
Stationary 
phase 
Sample 
Gas chromatography Gas Solid/liquid 
Gaseous sample (ordinary temperatures) 
Samples that vaporise (when heated) 
Liquid 
chromatography 
Liquid Solid/liquid 
Liquid samples 
Solid samples (solvent-soluble) 
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1.5.2.1. Liquid chromatography methods using ultraviolet, fluorescence and 
electrochemical detection  
Liquid chromatography (LC) is one of the most extensively used methods for the 
determination of 3-NT (Table III). Several different detectors have been employed, such as 
ultra-violet (UV), electrochemical (ECD), diode-array (DAD) and mass spectrometry (MS) 
(Tsikas, 2012).    
HPLC (High Performance Liquid Chromatography) is a chromatographic technique that can 
separate a mixture of compounds, and is used in biochemistry and analytical chemistry to 
separate, identify, quantify and purify the active compounds of a mixture (Naushad & Khan, 
2014). The principle behind this technique relies on the injection of the sample into a column 
that holds packing material (stationary phase), with further pumping of the mobile phase(s) 
through the column, at high pressure, and the detection through the retention times exhibited 
by the molecules. The retention time is based on differences in the migration rate through 
the column arising from different partitions of the sample in the stationary phase, the 
molecules being analysed, and the solvent(s) used. Commonly used solvents contain 
miscible combinations of water and organic liquids, the most common being methanol and 
acetonitrile. The gradient elution is responsible for separating the analyte mixture as a 
function of the affinity of the analyte for the mobile phase. The choice of solvents, additives 
and gradient can be influenced by the nature of both the stationary phase and the analyte 
(Meyer, 2013).   
HPLC is the standard technique for analysing amino acids, being the technique used by most 
laboratories (Ryberg & Caidahl, 2007). One of the first chromatographic methods for 
quantifying 3-NT uses isocratic reversed phase HPLC and UV absorbance detection at 274 
nm, as first reported by Kaur and Halliwell (Kaur & Halliwell, 1994). This HPLC-based 
method uses column with C-18, eluent (500 mM KH2PO4-F3PO4 with 10% methanol (v/v)), 
an acidic mobile phase (pH 3.01), and with a detection limit of 0.2 µM (Kaur & Halliwell, 
1994). Variants of this method have been used in several studies to determine 3-NT. Hitomi 
et al. (2007) performed an optimization of 3-NT separation process, showing that it depends 
on the mobile phase used. Moreover, the retention time depends on two factors, (i) the pH 
of the mobile phase, and (ii) the concentration of acetonitrile. The retention time was 
prolonged by a powerfully acidic mobile phase. 
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HPLC-UV detector. The HPLC-UV allows the detection of 3-NT as free amino acid, and 
associated with peptides and proteins as well (Yang, Zhang, & Pöschl, 2010) . Tyr and 3-
NT have a maximum absorbance at 280 nm in solution at pH 3.5. Additionally, 3-NT has a 
second absorbance at 357 nm. However, this second wavelength is more selective and, 
therefore, more suitable for detection purposes. In basic solutions (pH 9.5), 3-NT has a 
maximum absorbance at 430 nm (Herce-Pagliai, Kotecha, & Shuker, 1998; Yang et al., 
2010). The main drawback of this method is the lack of selectivity and sensitivity. HPLC 
coupled to ECD has the potential to be more selective than HPLC-UV or HPLC-fluorescent 
methods (Ryberg & Caidahl, 2007). 
  
HPLC-Diode Array Detector. Comparatively to UV detection, DAD allows the 
simultaneous detection at different wavelengths (Dong, 2006). Although HPLC-DAD is the 
most commonly used method for in vitro 3-NT analysis, it is not enough sensitive for in vivo 
quantitative analysis (Mergola et al., 2013). Recently, Selzle et al. (2013) developed a simple 
and efficient HPLC-DAD method for the determination of the nitration degree of small 
amounts of the birch pollen allergen Bet v 1. This method can be photometrically calibrated 
by the amino acids Tyr and 3-NT without the need for nitrated protein standards. The study 
also reported that this new method can be used in the investigation of the reaction kinetics 
and mechanism of protein nitration (Selzle et al., 2013).  
 
HPLC-fluorescence detection. Since 3-NT is not a fluorescent compound, it can only be 
detected using a fluorescence detector after structural modifications, such as the reaction of 
the amino group of 3-NT with a suitable derivatizing reagent (Herce-Pagliai et al., 1998). 
For instance, Pourfarzam et al. (2013) used 4-fluoro-7-nitrobenzo-2-oxa-l,3-diazole (NBD-
F) as derivatization reagent. This reagent has been reported in several studies and the results 
obtained were comparable among them (Pourfarzam et al., 2013). The fluorescent dyes used 
in the derivatization step of amino acids significantly improve the sensitivity and specificity 
of detection. NBD-F has a 10-fold higher sensitivity than ortho-phthaldialdehyde (OPA) 
(W.-Z. Zhang, Lang, & Kaye, 2007). The limitation of this method is that several fluorescent 
compounds are produced during the derivatization process (Herce-Pagliai et al., 1998). 
 
HPLC-Electrochemical detector. HPLC using ECD is relatively low-cost and has sufficient 
sensitivity for the measurement of 3-NT at moderately low basal levels found in most 
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biological samples from healthy individuals. These ECD-based methods have the potential 
to be more selective than HPLC-UV or HPLC-fluorescence methods, with a sensitivity about 
100-fold greater (Nuriel et al., 2008). 
The reproducibility of chromatogram signal intensity and retention time of 3-NT are 
determined by the quality of the C18 column used, as well as the appropriate maintenance 
of the electrochemical cell. Such reproducibility is ensured by (i) routine washing of the 
column with methanol, (ii) ensuring that potentials are not applied when the mobile phase is 
not flowing, and (iii) periodic reconditioning of the electrode when a performance loss is 
detected (Nuriel et al., 2008).  
1.5.2.2. Liquid chromatography-mass spectrometry methods 
One of the ways to overcome the limitations of HPLC is to couple it with an MS. This 
combination is advantageous for robust and unambiguous identification of compounds, 
especially when in the MS/MS mode (Ryberg & Caidahl, 2007; Tsikas & Duncan, 2014). 
Analytical methods based on MS-methodology are normally accepted as gold standards for 
the analysis of endogenous substances in biological fluids, owing to their high accuracy 
(Tsikas & Caidahl, 2005). The advantage of this technique is that it does not require sample 
derivatization to increase its volatility, unlike gas chromatography-mass spectrometry (GC-
MS), since it increases the likelihood of artefacts formation (Ryberg & Caidahl, 2007; Tsikas 
& Duncan, 2014).  
Nevertheless, liquid chromatography-mass spectrometry (LC-MS) does not offer the 
necessary selectivity for 3-NT measurement in biological sample, especially in human 
plasma (Ryberg & Caidahl, 2007; Tsikas & Duncan, 2014). One way to improve the 
selectivity and sensitivity for measurement is to use HPLC Hypercarb columns in triple-
stage quadrupole LC–ESI (Electrospray ionization) -MS/MS. The Hypercarb columns are 
composed of porous spherical carbon particles and the separation is based on the stronger 
retention time for polar compounds (Ryberg & Caidahl, 2007). 
Chen & Chiu (2008) developed a highly specific and accurate LC/MS/MS assay that allows 
simultaneous analysis of protein-bound 3-NT and 3-bromotyrosine (3-BT) in human urine. 
This proteins function as non-invasive biomarkers for in vivo PTN and bromination.  
In Table IV are described several liquid chromatography-based methods/ protocols for 
determination of 3-NT in biological samples that have been published over the last year. 
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Table III. Different HPLC-based methods used for the determination of 3-NT in biological samples 
Compound Sample Columna Eluents 
Flow rate 
(mL/min) 
Detection 
method 
3-NT, Tyr  
(Guvenç et al., 2014) 
Brain tissue 
Inertsil® ODS C18 
4.6 x 250; 5 
50 mM sodium  acetate (pH 4.2), 10% 
methanol (v/v) 
0.8 
DAD 
278 nm 
3-NT 
 (Sodum et al., 2000) 
Proteins from blood 
plasma 
Two ultrasphere ODS 
4.6 x 150; 3 
4.6 x 46; 5 
50 mM sodium acetate (pH 4.7), 5% 
methanol (v/v) 
0.7 
UV 
280 nm 
3-NT, p-nitro-L-
phenylalanine, and L-Tyr  
(Tsikas, Mitschke, Suchy, 
Gutzki, & Stichtenoth, 2005) 
Urine 
Nucleosil 100-5 C18 
4.0 x 250; 5 
50 mM (NH4)2SO4 in water-methanol (95:5, 
v/v)  (pH 5.5) 
1.0 
UV 
276 nm 
3-NT, Tyr  
(W.-Z. Zhang et al., 2007) 
Plasma 
Nova-Pak C18 
3.9 × 150; 4 
Mobile phase A: ACN and 0.02M  
phosphate buffer (pH 6.5; 90:10 v/v), 375 
µL/L TFA,  
5 mL/L 2-propanol (pH=4.5) 
Mobile phase B:  ACN and 0.02M  
phosphate buffer (pH 6.5; 10:90 v/v), 500 
µL/L TFA (pH 3.5) 
1.0 (34°C) 
UV 
540 nm 
3-NT  
(Ishida, Hasegawa, Mukai, 
Watanabe, & Nishino, 2002) 
Plasma 
SD ODS 
3.0 x 150; 5 
100 mM phosphate buffer solution, 5% 
methanol (v/v) 
0.5 (25°C) ECD 
3-NT  
(Hitomi et al., 2007) 
Rat plasma 
SC-50ODS 
3.0 x 150; 5 
200 mM phosphate buffer containing 
5mg/mL EDTA, 2% ACN 
0.5 ECD 
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Table III. (continued) 
Compound Sample Columna Eluents 
Flow rate 
(mL/min) 
Detection 
method 
3-NT  
(Bircan et al., 2011) 
Animal spleen tissues 
Microtech Scientific C18 
1.0 x 50; 5 
50 mM H3PO4, 50 mM citric acid, 40 mg/L 
EDTA, 100 mg/L octane sulfonic acid, 5% 
methanol (v/v) (pH 3.1 with KOH) 
0.05 ECD 
Free 3-NT Assay  
(Pourfarzam et al., 2013) 
Plasma 
Nova-Pak C18 
3.9 × 150; 4 
Sodium phosphate buffer (0.1 M, pH 7.2), 
methanol (52.5:47.5 v/v) 
1.0 
UV 
470 and 540 nm 
3-NT residues in protein  
(Yang et al., 2010) 
Bovine serum albumin 
and ovalbumin 
Grace Vydac 
2.1 x 250; 5 
0.1% (v/v) TFA in water and ACN 0.3 
DAD 
280 and 357 nm 
Tyr and 3-NT metabolites 
(Blanchard-Fillion et al., 
2006) 
Undifferentiated human 
teratocarcinoma NT2 and 
rat pheochromocytoma 
PC12 cell lines 
Octadodecyl silica gel 
reverse-phase column 
4.6 x 250; 5 
0.1% TFA in ultra pure water (solvent A) 
and 100% ACN (solvent B) 
1.0 
DAD 
215, 275, 365 
nm 
Tyr and 3-NT 
 (Kikugawa et al., 2004) 
Gaseous nitrogen oxide 
species 
Inertsil ODS-2 
4.6 x 250; 5 
0.5% (v/v) acetic acid:methanol (29:1, v/v) 1.0 
UV-VIS 
detector  
280 nm  
3-NT  
(Ueshima et al., 2007) 
Sputum and saliva 
C18 reversed phase 
column 
3.0 × 150; 5 
100 mM sodium phosphate buffer 
(pH 5.0), 5% methanol (v/v) 
0.5 ECD 
Free 3-NT 
 (F. Khan et al., 2006) 
Serum 
C18 reversed phase 
column 
4.6 x 250; 5 
500 mM potassium phosphate buffer  
(pH 3.5), 10% methanol (v/v) 
0.8 
UV 
274 nm 
a Column dimensions in the following order: internal diameter (in mm) x length (in mm); particle size (in µm).  
ACN, acetonitrile; EDTA, ethylenediamine tetraacetic acid; TFA, trifluoroacetic acid. 
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Table IV. Different liquid chromatography-based methods used for the determination of 3-NT in biological samples 
Compound Sample Columna Eluents Flow rate Detection method 
3-NT  
(Seeley et al., 2014) 
Microglial 
Cell Lysate 
EASY-Spray™ 
250 × 0.075; 2 
0.1% formic acid in water (mobile phase 
A) and 0.1% formic acid in ACN (mobile 
phase solvent B) 
350 nL/mim LC-MS/MS 
3-chlorotyrosine, 3-BT, 
and 3-NT  
(Gaut, Byun, Tran, & 
Heinecke, 2002) 
Plasma 
C18 reversed phase column 
Zorbax 
1.0 x 150;5 
Methanol/water/acetic acid (4/95/1,v/v/v, 
pH 3 – solvent A)  
+ 
methanol/water/acetic acid (95/4/1, v/v/v, 
pH=3.2 -solvent B) 
0.05 mL/min LC–MS/MS 
3-NT and 3-BT 
 (Chen & Chiu, 2008) 
Urine 
Reversed phase C18 column 
2.0 × 150; 5 
0.01% formic acid (pH 3.2) to 25% 
methanol in 0.01% formic acid 
0.2 mL/min LC–ESI/MS/MS 
3-NT 
 (Thornalley et al., 2003) 
Urine 
HypercarbTMc 
2.1 × 50; 5 
0.1% TFA with a linear 
gradient of 10–50% acetonitrile 
0.2 mL/min LC-MS/MS 
Free amino acid and 
protein 3-NT 
(Radabaugh et al., 2008) 
Biological 
fluids 
Immunoaffinity column: 
Targa 
4.6 x 30 
C18 reversed-phase 
column: Betasil 
2.1 x 100;5 
Immunoaffinity column: 1% formic acid 
C18 reversed-phase column: 100% 10 mM 
ammonium acetate acetonitrile 
Immunoaffinity 
column: 1 mL/min 
C18 reversed-phase 
column: 0.3 mL/min 
Immunoaffinity 
LC–MS/MS 
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Table IV. (continued) 
Compound Sample Columna Eluents Flow rate Detection method 
3-NT, 3-BT, 
Dibromotyrosine  
(Kato et al., 2009) 
Urine 
ODS-SR 
2 × 150; 5 
0.05% formic acid/CH3CN (95:5) Not stated LC/MS/MS 
Free 3-NT  
(Hui et al., 2012) 
Plasma 
Altima HP 
100 × 2.1 mm; 3 
Kinetex 
100 × 2.1; 2.6 
0.01% acetic acid in ultrapure water 
(mobile phase A)  
+ 
0.01% acetic acid in ACN ( mobile phase 
B) 
0.2 mL/min LC-MS/MS 
3-NT 
 (Nemirovskiy et al., 
2009) 
Plasma 
Immunoaffinity column: 
Targa 4.6 x 30 
C18 reversed-phase 
column: 2.1 x 100 
Immunoaffinity column: 1% formic acid 
solution 
C18 reversed-phase column: 100% 10 mM 
NH4OAc in H2O and 80% ACN 
1 mL/min 2D LC–MS/MS 
a Column dimensions in the following order: internal diameter (in mm) x length (in mm); particle size (in µm) 
ACN, acetonitrile; TFA, trifluoroacetic acid. 
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1.5.2.3. Gas chromatography-mass spectrometry methods  
GC-MS methodology is used for the analysis of volatile and thermally stable small 
molecules (Ryberg & Caidahl, 2007). When molecules to be analysed, such as amino acids, 
do not meet these features, a further derivatization step is required. In this sense, analysis of 
3-NT by this methodology requires prior chemical derivatization and/or modification of the 
functional groups (i.e., p-OH, a-NH2, and COOH) to increase volatility and thermal stability 
(i.e., reduction of the aromatic NO2 group). In addition, derivatization improves GC and MS 
behaviour of 3-NT (Tsikas & Duncan, 2014). Derivatization, however, often accounts for 3-
NT artefact formation, which is may be responsible for high variation of basal plasmatic 3-
NT levels (Tsikas & Caidahl, 2005). Nevertheless, GC-tandem MS is described as a 
methodology that allows the accurate quantification of free 3-NT in human plasma at basal 
levels. GC-tandem MS is more accurate than GC-MS (Tsikas & Caidahl, 2005; Tsikas et al., 
2005). Table V summarises different gas chromatography-based methods for determination 
of 3-NT in biological samples. 
The GC-MS and GC-MS/MS methods for the analysis of 3-NT involve the preparation of 
perfluorinated derivatives. Perfluorinated compounds are strong electron-capturing species, 
thus offering assays of particularly high sensitivity (Tsikas & Duncan, 2014). 
Gaut et al. (2002) reported that GC–MS was 100-fold more sensitive than LC–tandem MS 
for the analysis of 3-NT. The major drawback of this method is that 3-NT is not suitably 
separated from Tyr, nitrite and nitrate prior to GC–MS analysis or derivatization. Such 
separation could potentially be achieved, for instance, by HPLC (Tsikas, 2012).  
In the study performed by Söderling et al. (2003), the derivatization method used was based 
on the reduction of the nitro group of 3-NT by dithionite, heptafluorobutyric acylation and 
subsequent methyl derivatization. Their results demonstrated excellent GC and MS 
properties, namely low background and a favourable fragmentation pattern (Söderling et al., 
2003). 
In fact, the major strategies used to avoid artifacts formation are (i) isolation of 3-NT by SPE 
and HPLC; (ii) reduction of 3-NT to 3-amimotyrosine before sample derivatization, thus 
artifactual nitration of Tyr does not influence the measurement; (iii) use of high 
concentrations of reactive aromatic compounds (i.e., phenol) to capture nitrosating species; 
and (iv) quantification of artifactual 3-NT formation, by incorporating stable-isotope 
labelled Tyr (e.g., 13 C6 -Tyr) into each sample (Tsikas & Duncan, 2014). Overall, the main 
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disadvantage of using chromatographic methods is that they involve time-consuming sample 
preparation procedures (Weber et al., 2012).  
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Table V. Different gas chromatography-based methods used for the determination of 3-NT in biological samples 
Compound Sample Columna Eluents Detection method 
3-NT 
(Tsikas et al., 2005) 
Urine 
Optima 5-MS 
30 x 0.25; 0.25 
Helium (55 kPa); Methane (530 Pa) and Argon 
(0.27 Pa collision pressure) 
GC–MS/MS 
Protein-associated 3-NT and 
3-nitrotyrosinoalbumin 
(Tsikas et al., 2003) 
Plasma 
Optima 5-MS 
30 x 0.25; 0.25 
Helium (55 kPa); Methane (530 Pa) and Argon 
(0.27 Pa) 
GC–MS/MS 
3-NT 
(Ryberg et al., 2004) 
CSF 
DB-1 MS column 
15 × 0.32 ; 0.25 
Helium (3psi); Methane (750-800 Pa) GC–MS/MS 
3-NT 
(Söderling et al., 2003) 
Plasma 
DB5-MS column 30 
x 0.25; 0.25 
Helium (41 kPa); Methane (0.27-1.1 kPa) GC–MS/MS 
Free 3-NT 
(Lärstad, Söderling, Caidahl, & 
Olin, 2005) 
Exhaled breath 
condensate (EBC) 
DB5-MS column 
30  x 0.25; 0.25 
Helium (38 kPa); Methane (0.97-0.99 kPa) GC/NICI/tandem MS 
a Column dimensions in the following order: internal diameter (in m) x length (in mm); particle size (in µm) 
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1.6. Objectives of this thesis 
As previously stated, nitration of proteins is a common process that occurs under 
physiological conditions. On the other hand, a significant increase in the extent of this 
process, induced by an increased nitrosative stress state, has been associated with a wide 
range of diseases.  Previous published studies have shown that other biomarkers of oxidative 
stress may be a useful tool for therapeutic monitoring (Joly & Grunfeld, 2014; Peixoto, 
2012). In this sense, the main goal of this project was to develop a sensitive, simple, low-
cost 3-NT quantification method for use in medical laboratories as a tool for diagnosis and/ 
or treatment monitoring of a wide range of pathologies.  
This goal was achieved through the following tasks: 
(i) Development and validation of the method for 3-nitrotyrosine quantification (chapter 
II); 
(ii) Evaluation of the applicability of the aforementioned chromatographic method in 
different samples (chapter III).  
Lastly, chapter IV shows the overall conclusions, limitations as well as future perspectives 
of this study.  
 
 
 
 
 
 
 
 
  
 
  
    
 
 
Chapter II 
Development and validation of the method for 3-nitrotyrosine quantification 
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2.1. Introduction  
2.1.1. General concept of a High-performance liquid chromatography system  
An HPLC system is composed by several specialized sectors interconnected to each other 
by a thin tube system that allows the movement of the mobile phase between them (Figure 
4). The major components of a classic HPLC system are described in detail below (Dong, 
2006; Rouessac & Rouessac, 2013). 
Pump. The role of the pump is to force the mobile phase through the column which packing 
is fairly compact. The pump allows to maintain a constant flow regardless of the pressure. 
The pressure depends on (i) the flow rate, (ii) the viscosity of the mobile phase and (iii) the 
particle size of the stationary phase. Generally, the pump contains two pistons, and is capable 
of delivering an eluent of fixed (isocratic) or variable composition to create an elution 
gradient (Baker, Dunn, Lajtha, & Holt, 2007; Rouessac & Rouessac, 2013).  
Injector. The injector allows to introduce a precise volume of sample onto the head of the 
column in a rapid manner. The importance of these injectors relies on the minimization of 
flow disturbances due to the dynamic regime of the mobile phase, which permits a stable 
flow from the column to the detector (Rouessac & Rouessac, 2013).  
 Figure 4 Schematic representation of a modular HPLC instrument. 
The chromatography allows the separation of a complex mixture into its individual compounds. The 
separation is performed between a mobile phase and a stationary phase. The HPLC is composed by mobile-
phase reservoirs, pumps, mixer to mix the solvents, a valve into which the sample is injected, a guard column, 
a column containing the stationary phase, a detector, and a recorder. 
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Column. The column is regarded as the major component of an HPLC system. The column 
is a straight stainless steel calibrated tube and coated with an inert material, such as spherical 
silica gel beads, polymers and alumina (Kazakevich & LoBrutto, 2007).  This column should 
be changed from time to time and it is recommended, prior to analysis, to pass the samples 
through a filter of pore size less than 0.5µm  in order to enlarge column’s time of life 
(Rouessac & Rouessac, 2013).   
Stationary phase. The stationary phase is the second medium in which the compounds 
initially dissolved in the mobile phase will interact. The spherical silica gel is the basic 
material mostly used in HPLC columns packaging (Rouessac & Rouessac, 2013). The silica 
matrices are robust and very polar and form a three-dimensional network. This matrix can 
be chemically modified by a derivatisation process through hydrophobic ligands, providing 
the original surface with a higher level of hydrophobicity. For instance, the ligand dimethyl 
octadecylsilane (ODS) is often used in such derivatisation process, being mostly applied in 
protocols for the reverse phase-HPLC (RP-HPLC) analysis of peptides and proteins (Fanali, 
Haddad, Poole, Schoenmakers, & Lloyd, 2013; Rouessac & Rouessac, 2013).  
Mobile phase. The interaction between the mobile and the stationary phases affects the 
retention time of the analytes. If the stationary phase is polar, the mobile phase should be 
less polar. On the other hand, if the stationary phase is non-polar, the mobile phase should 
be polar. Regarding the latter case, the mobile phase is often made up of water with a 
modifying organic solvent (e.g., methanol or acetonitrile) (Buszewski & Noga, 2012; 
Rouessac & Rouessac, 2013). 
Detector. Detectors permit continuous registration of specific physical and chemical 
proprieties of the column effluent (Kazakevich & LoBrutto, 2007). HPLC-based methods 
employ a wide range of detection strategies based on the analytes proprieties, such as 
spectrophotometry, fluorescence detection and refractive index (Baker et al., 2007; Rouessac 
& Rouessac, 2013). 
2.1.2. Theory of reversed phase chromatography  
In simplistic terms, chromatography involves passing a mixture dissolved in the mobile 
phase trough a stationary phase, which separates the analyte to be measured from other 
molecules present in the mixture. Such separation process is based on the differential 
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partitioning effect between the mobile and stationary phases (Mullangi, Sharma, & Srinivas, 
2012).   
Reversed-phase chromatography involves the separation of molecules on the basis of their 
hydrophobicity. This separation depends on the hydrophobic binding interaction between 
the solute molecules from the mobile phase and the immobilized hydrophobic ligands from 
the stationary phase (Fanali et al., 2013) (Figure 5).   
2.1.2.1. Critical parameters in reversed phase chromatography  
Column length. The essential parameters of any chromatographic column are its (i) 
permeability, (ii) efficiency, and (iii) retention ability (Guiochon, 2007) .  
The resolution of small organic molecules in reversed phase separations is more sensitive to 
column length than in high molecular weight molecules. The resolution of small peptides 
may sometimes be improved by increasing column length. In the case of small changes in 
the organic modifier concentration of the mobile phase, the resolution is increased by using 
a longer column (Biotech, 2002).  
The column length may not be a critical parameter in the separation resolution when gradient 
elution is used. Using elution gradient is particularly advantageous in biological samples that 
contain a mixture of molecules with different adsorption affinities (Gad, 2007).  
Flow rate. One important factor in the resolution of small molecules in reversed phase 
separations is the flow rate. Nevertheless, larger biomolecules appear to be insensitive to 
flow rate. In analytical protocols, the flow rate is especially important during the loading of 
Figure 5. Principle of separation of reversed-phase chromatography. 
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a large number of samples. Flow rate may also influence the dynamic binding capacity of 
the gel, which reflects the kinetics of the solute binding process during the loading stage 
(Biotech, 2002). 
Temperature. The temperature is a critical factor in reversed phase chromatography, 
particularly when analysing small molecules. It is known that column temperature affects 
both time retention and selectivity. In this case, increasing the temperature is theoretically 
effective (Guillarme, Heinisch, & Rocca, 2004). Increased temperatures are known to 
decrease mobile phase viscosity used in reversed phase chromatography (Guillarme et al., 
2004). In turn, viscosity influences the method resolution, as a decrease in this parameter 
leads to an increased resolution (Clark, 2004). 
Mobile phase. Mobile phase used in reversed phase chromatography is commonly made up 
of strong acids with large concentrations of organic solvents. However, and when 
physiological conditions needs to be mimicked, a buffer (e.g. phosphate buffer) is often used 
as mobile phase (Taylor, 2014). 
2.1.3. HPLC method development  
Analytical method development and validation is a four-step process. Briefly, HPLC method 
development includes (i) selection of the method and system, (ii) selection of initial 
conditions, (iii) method optimization, and (iv) validation. 
2.1.3.1. Selection of the method and initial system 
The first step is to check whether similar protocols have previously been published, allowing 
a more cohesive and less time consuming start point (Murugan et al., 2013). In this initial 
step, the type of HPLC is selected, and the physicochemical properties of the molecule as 
well as the sample preparation process are evaluated (Fergusom & Huet, 2011; Gupta, Jain, 
Gill, & Gupta, 2012; Murugan et al., 2013). 
Physicochemical proprieties of the molecule to study play an important role in method 
development (Carini, Kaiser, Ortega, & Bassani, 2013; Gupta et al., 2012). The properties 
to take into account usually include (i) solubility (which influences the solvent selection), 
(ii) polarity (to choose the solvent and composition of the mobile phase), (iii) pKa and (iv) 
pH (Gupta et al., 2012; Murugan et al., 2013). The sample should ideally be dissolved in the 
mobile phase. When not possible, additives may be used, such as formic acid, acetic acid 
and salts (Murugan et al., 2013). 
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2.1.3.2.  HPLC conditions  
Selection of the optimal conditions are pivotal for a successful method development process. 
However, a wide range of parameters needs to be carefully examined in advance. 
Buffer selection. The selection of buffer is based on the desired pH. The recommended pH 
range for reversed phase on silica-based packing is between 2 and 8. Buffers have a pKa 
close to the recommended pH range and are usually used to adjust the pH of the mobile 
phase (Fergusom & Huet, 2011). The pH of the mobile phase is an important parameter to 
bear in mind since it determines the chromatographic retention of various analytes with acid-
base properties (Roses, 2004). 
Buffer concentration. For small molecules, the buffer concentration range is usually 10-
50nM, with an organic solvent content <50%. The most common buffers used in reversed 
phase protocols are sodium and potassium salts (Gupta et al., 2012).   
Isocratic or gradient separations. Regarding the mobile phase composition, two main 
strategies are commonly used: isocratic or gradient elution. When applying an isocratic 
elution, the mobile phase composition and the velocity of the compounds moving through 
the column remains constant throughout the separation process (Gupta et al., 2012). On the 
other hand, a gradient elution implies that the mobile phase composition is changed during 
the analysis, which can be achieved through different approaches (linear, segment, convex 
and concave gradient). The selection of the gradient mode to be used should allow a reduced 
time analysis as well as a high resolution  (V. S. Joshi, Kumar, & Rathore, 2015).  
2.1.3.3. Method optimization  
After a general selection of the initial conditions, it is essential to optimize them so that 
satisfactory sensitivity and efficient chromatographic separation can be achieved. The 
optimization process comprises different stages, and the time consumed on this step depends 
on the number of variables to be adjusted. Experimental variables often include pressure, 
temperature, column length, mobile phase and flow rate (Wang, Carr, & Stoll, 2010).  
2.1.3.4. Method Validation 
The validation step is extremely important since it assures that the analytical method 
optimized is suitable for the intended purpose. Validation data should provide detailed 
description of the method, including demonstration of compliance with acceptance criteria 
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approved by a recognised entity following current good laboratory practice (FDA, 2015). 
This step is of particular importance for methods to be used in medical laboratories (Kumar, 
Sreenivasa Reddy, Managuli, & Pai K, 2015). 
Q2 (R1) guideline from International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) is considered the 
primary reference for recommendations and definitions on validation of analytical methods 
(FDA, 2015; ICH, 2005; Sonawane, Poul, Usnale, Waghmare, & Surwase, 2014). Directive 
96/23/EC concerns to the performance of analytical methods and to the interpretation of 
results (European Commission, 2002).  
2.1.3.5. Validation of parameters 
The parameters defined by ICH for validation of analytical methods are briefly described in 
Table VI. 
Table VI. Parameters defined by ICH for validation of analytical methods 
Parameters  Description  
Specificity ICH defines specificity as “the ability to assess unequivocally the analyte in the presence 
of components which may be expected to be present. Typically this might include 
impurities, degradants, matrix, etc.” This definition implies the identification of an analyte 
and a purity test.  
Linearity 
The linearity in an analytical procedure that allows to obtain test results directly 
proportional to the concentration (amount) of analyte in the sample;   
The linearity should be determined at least with a series of five patterns for which the 
expected concentrations should cover 80%-120% of the desired concentration. The result 
should be proportional to the concentrations of the analytes and it should be evaluated by 
appropriate statistical methods, for example, by calculation of a regression line by the 
method of least squares.  
Accuracy  
The accuracy of an analytical method is defined by the closeness of test results obtained 
by that method to the true value or to an accepted reference value.  
Accuracy may be determined through different ways: (i) by analysing a sample of known 
concentration (reference material), and comparing the measured value to the true value; 
(ii) by comparing test results from the new method with those of a second well-
characterized procedure, the accuracy of which is stated and/or defined; (iii) based on the 
recovery of known amounts of analyte (minimum to prepare in triplicate at three levels) 
and (iv) based on the recovery of spiked analyte with standard additions. 
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Table VI. (continued) 
Parameters  Description  
Precision Precision is an analytical procedure that enables to evaluate the closeness of agreement 
between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. 
Repeatability Repeatability express the precision operating over a short time 
interval under the same condition (intra-assay precision); 
It should be assessed using a minimum of nine determinations 
covering the specified range of the procedure (for example, three 
levels, three repetitions each), or from a minimum of six 
determinations at 100% of the test concentration. 
Intermediate 
precision 
The intermediate precision consists in the comparison of the results 
of a method run within a single laboratory over a number of days. 
This precision may reflect discrepancies in results obtained from 
different operators, different instruments standards and reagents 
from different suppliers or others.  
Reproducibility Reproducibility is assessed between laboratories by means of an 
inter-laboratorial trial.  
Range  The range of an analytical produce provides an acceptable degree of linearity, accuracy 
and precision when applied to samples containing amounts of analyte within or at the 
extremes of the specified range of the analytical procedure. 
Limit of 
detection 
The limit of detection (LoD) is the point at which the lowest concentration of analyte in a 
sample can be detected but not essentially quantitated as an exact value. 
 Visual evaluation Visual evaluation is determined by the (i) analysis of samples with 
known concentration of analyte and by (ii) establishing the minimum 
level at which the analyte can be reliably detected.  
 Signal-to-Noise The signal-to-noise ratio determination is performed by comparing 
measured signals from samples with known low concentrations of 
analyte with those of blank samples and establishing the minimum 
concentration at which the analyte can be reliably detected. A signal-
to-noise ratio between 3 or 2:1 is normally considered satisfactory 
for estimating the detection limit. 
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Table VI. (continued) 
Parameters Description 
 Standard 
deviation of the 
response and 
slope 
The LoD may be expressed as: 𝑳𝒐𝑫 =
𝟑.𝟑𝝈
𝑺
  
σ = the standard deviation of the response  
S = the slope of the calibration curve 
The σ may be estimated by the following  ways:  
Based on the Standard Deviation of the Blank - analysing an 
appropriate number of blank samples and calculating the standard 
deviation 
Based on the Calibration Curve - using samples containing an 
analyte in the range of LoD. The standard deviation may be 
calculated by the residual standard deviation of a regression line or 
by the standard deviation of y-intercepts of regression lines.  
Limit of 
quantification  
The limit of quantification (LoQ) is the lowest amount of analyte in a sample which can 
be quantitatively determined with suitable precision and accuracy.   
Visual evaluation Visual evaluation determined by the (i) analysis of samples with 
known concentrations of analyte and by (ii) setting the minimum 
level at which the analyte can be quantified with acceptable accuracy 
and precision 
Signal-to-Noise The signal-to-noise ratio determination is performed by comparing 
measured signals from samples with known low concentrations of 
analyte with those of blank samples and establishing the minimum 
concentration at which the analyte can be reliably detected.  
Standard 
deviation of the 
response and 
slope 
The LoQ may be expressed as: 𝑳𝒐𝑸 =
𝟏𝟎𝝈
𝑺
  
σ = the standard deviation of the response  
S = the slope of the calibration curve 
The σ may be estimated by following  ways:  
(i) Based on the Standard Deviation of the Blank - analysing an 
appropriate number of blank samples and calculating the standard 
deviation 
(ii) Based on the Calibration Curve - using samples containing an 
analyte in the range of LoQ. The standard deviation may be 
calculated by the residual standard deviation of a regression line or 
by the standard deviation of y-intercepts of regression lines. 
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Table VI. (continued) 
Parameters  Description  
Robustness Robustness should be determined during the development phase, and provides an 
indication of the procedure’s analysis reliability in relation to deliberate variations in 
method. 
Parameters that affect robustness often include (i) pH, (ii) mobile phase composition; (iii) 
flow rate, (iv) column temperature, and (v) column type.  
Reference: (FDA, 2015; Huber, 2010; ICH, 2005) 
2.1.4. Aim 
The aim of this chapter was to develop a suitable method for use in most clinical laboratories. 
Therefore, and taking into account all the positive and negative features of the methods 
described throughout Chapter I, we defined as major pre-requisites i) availability of the 
equipment in a wide range of medical laboratories, ii) reduced pre-analysis steps, and iii) 
cost-effective analysis. After an exhaustive analysis, we found that an HPLC-based method 
would perfectly meet the previous pre-requisites.  
In chapter II is described the first three steps of the method development stage: i) selection 
of the method and system, (ii) selection of initial conditions, (iii) method optimization and 
method validation. Regarding optimization, different mobile phases were tested in order to 
find one exhibiting well-defined peaks, a good LoD and LoQ, a good linearity and reduced 
time analysis. 
2.2. Material and Methods  
2.2.1. Instrument and software 
All experiments were performed on a Hitachi LaChrom Elite® HPLC system (Hitachi High 
- Technologies Corporation, Tokyo, Japan) composed by HTA L-2130 LaChrom Elite 
quaternary pumps (Hitachi High-Technologies Corporation), L-2200 LaChrom Elite 
autosampler (Hitachi High-Technologies Corporation), L-2300 LaChrom Elite column 
heater (Hitachi High-Technologies Corporation), L-2455 LaChrom Elite photo DAD 
(Hitachi High-Technologies Corporation). EZChrom Elite Compact Software Version 3.3.2. 
(Agilent Technologies, Inc., Santa Clara, CA, United States) was used for data collection 
and treatment.  
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2.2.2. Reagents and consumables  
3-Nitro-L-tyrosine was purchased from Santa Cruz Biotechnology, Inc. (Bergheimer, 
Heidelberg, Germany). L-Tyrosine was purchased from AppliChem - BioChemia GmbH 
(Ottoweg, Darmastadt, Germany). Glacial acetic acid (100%) was purchased from Merck 
S.A. (Algés, Portugal). Methanol (HPLC GOLD Ultra Gradient) was purchased from Carlo 
Erba Reagents (Chaussée du Vexin, Val de Reuil, France). Ultrapure water was obtained 
from the Water Purification System TKA Barnstead™ GenPure™ capsule 0.2µm (Thermo 
Fisher Scientific, Wilmington, DE, EUA). Trifluoroacetic acid was purchased from Biochem 
Chemopharma (Ligne, Cosne sur Loire, France). LiChrospher® 100 RP-18 (5 µm) 
LiChroCART® 250-4 was purchased from Merck S.A. (Algés, Portugal). Membrane filters 
0.45µm, 47mm, were purchased from Advantec®, Toyo Roshi Kaisha, Ltd. (Tokyo, Japan). 
PuradiscTM, 0.2 µm, 25mm sterile and endotoxin free filters were purchased from 
WhatmanTM (GE Healthcare UK Limited, Buckinghamshire, UK). 2 mL syringes were 
purchased from Terumo® Medical Corporation (Leuven, Belgium).  
2.2.3. Analytical procedure  
2.2.3.1. Mobile phase – 500 mM KH2PO4 (pH 3.5) 
KH2PO4 solutions were prepared in three different concentrations: 500 mM plus 10% MeOH, 
50 mM, and 25 mM. All solutions were adjusted to pH 3.5 using a 1M H3PO4 solution. 
2.2.3.2. Mobile phase – 0.5% CH3COOH:MeOH:H2O  
0.5% CH3COOH:MeOH:H2O solutions were prepared according the following proportions:  
29:1:70 (Kikugawa et al., 2004), 30:0:70, and 15:15:70.  
All mobile phases, including those prepared in 2.2.3.1, were filtered through a 0.45µm 
membrane. 
2.2.3.3. Calibration standards  
0.5 mg/mL 3-NT and Tyr stock solutions were made using the aforementioned mobile 
phases as solvents. All stock solutions were filtered through a filter membrane device. The 
first assays were performed using standard solutions containing either 3-NT or Tyr in the 
following concentrations (100000; 50000; 25000; 10000; 5000 ng/mL). In the subsequent 
assays, standard solutions containing both 3-NT and Tyr were prepared in the following 
concentrations (50000; 25000; 10000; 5000; 2500; 1250; 625 and 312.5 ng/mLStandard 
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solutions were prepared by diluting the respective stock solution into the desired mobile 
phase. When required, heat was used in order to better dissolve the reagents. These standard 
solutions were used for calibration purposes.  
2.2.3.4. Chromatographic conditions  
Table VII shows the chromatographic conditions used in all assays described in this study. 
 
2.2.4. Method optimization 
2.2.4.1. Optimization of Tyr standard preparation 
0.4 mg/mL Tyr stock solutions were prepared using the following solvents: 
(a) PBS pH 7.35; 
(b) ultrapure water; 
(c) acidified ultrapure water; 
(d) mobile phase (0.5% CH3COOH:MeOH:H2O 15:15:70, v/v) 
2.2.4.2. Optimization of the temperature  
In order to find out the best operating temperature, a wide range of temperatures (15, 20, 35, 
45, 55 and 65ºC) were assayed using two standard solutions (50000ng/mL and 25000 ng/mL) 
and two samples (serum). 
2.2.5. Method validation  
All the methods tested were validated according to ICH guidelines for validation of 
analytical procedures (ICH, 2005).  
2.2.5.1. Specificity 
The specificity of the methods was determined by comparing chromatograms obtained from 
3-NT and Tyr spiked-samples.  
Table VII. Chromatographic conditions 
Flow rate* Volume of injection Detection 
1mL/min 25 µL 190-400 nm 
* When 500 mM KH2PO4, 10% MeOH was used, assays were carried out at flow rate of 0.8 mL/min 
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2.2.5.2. Linearity  
Six to eight standard solution concentrations comprising the range between 312.5 - 50000 
ng/mL were assayed. Calibration curves were constructed by plotting average peak area 
versus concentrations. The linearity was evaluated using regression analysis.  
2.2.5.3.  Accuracy  
Accuracy was determined by measuring recovery in 3-NT-spiked serum samples (3 different 
concentration levels: 25000, 1000, and 50 ng/mL) and in standard solutions (50000, 25000, 
10000, 5000, 2500, 1250, 625, 312.5 ng/mL).  
2.2.5.4. Precision  
Precision was determined by means of the repeatability (intraday precision). The 
repeatability was evaluated by analysing standard solutions (8 concentration levels: 50000, 
25000, 10000, 5000, 2500, 1250, 625, 312.5 ng/mL) and 3-NT-spiked serum samples (3 
different concentration levels: 25000, 1000, 50 ng/mL). 
2.2.5.5. LoD and LoQ  
LoD and LoQ were determined using the following equations: 
𝑳𝒐𝑫 =
𝟑.𝟑𝝈
𝑺
  
𝑳𝒐𝑸 =
𝟏𝟎𝝈
𝑺
  
Where δ is the standard deviation of the blank and S is the slope retrieved from the calibration 
curve data. 
2.2.6. Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 6.02 (La Jolla, CA, USA). 
Calibration curves equations were obtained using linear regression analysis. 
2.3. Results and discussion  
A wide range of methods for 3-NT detection and quantification has been developed during 
the last years, all of them presenting positive and negative aspects. Regarding ELISA-based 
methods, and despite being the least time-consuming and most straightforward methods, it 
has become clear that they do not provide the most accurate results. On the other hand, and 
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in relation to chromatographic methods, they seem to be very accurate, showing very good 
sensibility and specificity. GC-based methods exhibit the highest sensibility in the 
quantification of 3-NT. However, and owing to 3-NT chemical properties, a derivatization 
step prior to analysis is required, which ends up being time-consuming for the analyst. 
Moreover, derivatization reactions often induce artifacts formation, which may further 
influence the final analysis. Conversely, HPLC does not require such derivatization step, 
despite being not as accurate as GC.  
The development and validation of an HPLC-based method are, as for any other analytical 
method, an important requirement for quality assurance purposes. Thus, our HPLC assays 
were performed and the results interpreted according to ICH guidelines (ICH, 2005) and 
96/23/EC directive (European Commission, 2002). 
Firstly, the critical parameters (wavelength of detection, composition of mobile phase, 
optimum pH, temperature and concentrations of standard solutions) were studied in detail in 
order to develop an effective method for quantification of 3-NT. All chromatographic assays 
were performed using a C18 column, which is regarded as the most appropriate type for RP-
HPLC analysis of peptides and proteins (Aguilar, 2004). 
Concerning the wavelength of detection, DAD was used in order to obtain 3-NT and Tyr 
absorbance spectra. 3-NT and Tyr-containing solutions were run and detected within the 
ultraviolet range (190-400 nm). Maximum absorbance values were found at 215, 276 and 
356 nm for 3-NT (Figure 6), and 196, 223 and 274 nm for Tyr (Figure 7). Accordingly, we 
defined 215, 276 and 356 nm as the optimal wavelengths of detection for our subsequent 
assays. 
With regards to the second critical parameter, mobile phases were prepared with different 
methanol concentrations. The composition of the mobile phases to be assayed were selected 
based on the (i) information shown in Table VIII, and (ii) pH range (Ahuja & Dong, 2005; 
D. D. Joshi, 2012). In general, a pH range between 2-3 is a good starting point in a method 
development process. This pH range suppresses the ionization of most acidic compounds 
and the ionization of any silanol groups present on the column. On the other hand, basic 
compounds may be ionized under these conditions. Nevertheless, operating at high pH 
values to suppress such ionization process may be detrimental for most columns (Ahuja & 
Dong, 2005).  
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2.3.1. Mobile phase: KH2PO4 
The first step in our method development process was the selection of the mobile phase to 
be used in our assays. F. Khan et al. (2006) used potassium phosphate buffer (500 mM, pH 
3.5) with 10% MeOH (v/v), as mobile phase for detection and quantification of 3-NT, 
claiming good results. As a first approach, we also tested this mobile phase, which has 
revealed quite satisfactory results, well-defined peaks (Figure 7), short time of analysis, as 
well as LoD and LoQ on the order of tens of nanogram per mililiters (Table VIII). The LoD 
and LoQ were established by evaluating the minimum level at which the analyte could be 
readily detected and quantified accurately, respectively  (Thakkar, Saravaia, Ambasana, 
Kaila, & Shah, 2011).  
However, this mobile phase has also revealed a worrisome problem: the precipitation of 
potassium phosphate within the HPLC tubing system, leading to increased pressure and 
column clogging. Consequently, the results of the last samples were pretty difficult to 
analyse due to column obstruction.  
Figure 6. 3-NT and Tyr absorption spectra, obtained by DAD. 
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Table VIII. Description of the assays performed, and respective retention time (mean ± standard deviation), 
LoD and LoQ values; n/a not applicable 
Mobile phase Composition Assay 
KH2PO4 
500mM KH2PO4, 10% MeOH A 
50mM KH2PO4 B 
25mM KH2PO4 C and D 
0.5%CH3COOH:MeOH:H2O 
29:1:70 E and F 
30:0:70  G and H 
15:15:70 I and J 
(A) 
Retention time 
(min) 
LoD 
(ng/mL) 
LoQ 
(ng/mL) 
Flow 
(mL/min) 
Column oven 
temperature (ºC) 
Analysis 
time 
(min) 
3-NT (220nm) 9.959 ± 0.820 24.22 73.40 
0.800 35 15 
3-NT (276nm) 9.973 ± 0.818 40.38 122.37 
3-NT (356nm) 9.947 ± 0.806 87.33 264.63 
Tyr (220nm) 3.741 ± 0.120 21.40 64.84 
Tyr (276nm) 3.593 ± 0.224 37.15 112.58 
(B)       
3-NT (220nm) n/a n/a n/a 
1.000 25 15 
3-NT (276nm) n/a n/a n/a 
3-NT (356nm) n/a n/a n/a 
Tyr (220nm) 7.423 ± 0.058 0.06 0.17 
Tyr (276nm) 7.425 ± 0.055 0.33 1.01 
(C)       
3-NT (220nm) n/a n/a n/a 
1.000 25 25 
3-NT (276nm) n/a n/a n/a 
3-NT (356nm) n/a n/a n/a 
Tyr (220nm) 7.247 ± 0.011 0.17 0.51 
Tyr (276nm) 7.244 ± 0.023 0.86 2.62 
(E)       
3-NT (220nm) 28.683 ± 0.128 6.91 20.93 
1.000 25 40 
3-NT (276nm) 28.644 ± 0.110 1.76 5.32 
3-NT (356nm) 28.583 ± 0.220 71.32 216.11 
Tyr (220nm) 8.170 ± 0.031 0.45 1.36 
Tyr (276nm) 8.153 ± 0.043 0.76 2.29 
(F)       
3-NT (220nm) 18.819 ± 0.053 0.26 0.80 
1.000 40 30 
3-NT (276nm) 18.813 ± 0.055 0.44 1.33 
3-NT (356nm) 18.805 ± 0.082 44.05 133.48 
Tyr (220nm) 5.870 ± 0.017 0.17 0.52 
Tyr (276nm) 5.874 ± 0.021 60.85 184.39 
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Table VIII. (continued) 
(G) 
Retention time 
(min) 
LoD 
(ng/mL) 
LoQ 
(ng/mL) 
Flow 
(ml/min) 
Column oven 
temperature (ºC) 
Analysis 
time 
(min) 
3-NT (220nm) 34.178 ± 0.107 10.60 32.13 
1.000 25 40 
3-NT (276nm) 34.198 ± 0.118 36.97 112.02 
3-NT (356nm) 34.184 ± 0.161 36.15 109.53 
Tyr (220nm) 8.929 ± 0.049 0.72 2.18 
Tyr (276nm) 8.926 ± 0.064 66.82 202.50 
(H)       
3-NT (220nm) 21.801 ± 0.119 2.90 9.67 
1.000 40 35 
3-NT (276nm) 22.885 ± 0.125 44.35 134.40 
3-NT (356nm) 22.884 ± 0.148 8.46 25.65 
Tyr (220nm) 6.734 ± 0.051 0.61 1.84 
Tyr (276nm) 6.734 ± 0.050 1.37 4.15 
(I)       
3-NT (220nm) 7.133 ± 0.041 0.34 1.04 
1.000 25 15 
3-NT (276nm) 7.133 ± 0.043 0.85 2.56 
3-NT (356nm) 7.133 ± 0.042 1.22 3.71 
Tyr (220nm) 3.479 ± 0.019 0.10 0.29 
Tyr (276nm) 3.480 ± 0.019 0.26 0.78 
(J)       
3-NT(220nm) 9.878 ± 0.080 6.09 18.47 
1.000 25 15 
3-NT(276nm) 9.878 ± 0.079 0.93 2.81 
3-NT(356nm) 9.878 ± 0.081 5.11 15.49 
Tyr (220nm) 4.145 ± 0.023 1.81 5.49 
Tyr (276nm) 4.146 ± 0.022 0.53 1.60 
Figure 7. Representative chromatograms of (a) Tyr and (b) 3-NT analysis using mobile phase A 
(500mM KH2PO4, 10%MeOH). 
b) a) 
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In order to wash the HPLC system the following steps were carried out: (i) the column was 
removed and washed with ultrapure water between 40-50°C for about 30 min. (time required 
to remove phosphate precipitates); (ii) the column was put back and washed again with 
ultrapure water between 40-50°C during 10 min.; (iii) the steps (i) and (ii) were repeated 
until the pressure dropped down; (iv) once the pressure was stabilized, the column was 
washed with a mixture of MeOH:ultrapure water 50:50 for 10 minutes, and then washed 
with 100% MeOH. This last step was carried out after carefully ensuring that no precipitate 
remained in the system, otherwise the use of 100% MeOH would worsen the precipitate 
formation problem. Furthermore, caution was taken in order to minimize the contact time 
between the column and 100% ultrapure water. 
Common factors favouring buffer precipitation are (i) high phosphate buffer concentrations, 
and (ii) reaction between phosphate and the organic solvent. According to the literature, 
phosphate buffer concentration should be about 10-50 mM for analysis of small molecules, 
since this concentration range provides the required buffering capacity (Ahuja & Dong, 
2005; D. D. Joshi, 2012). In order to overcome the precipitation issue, we performed a 1:10 
dilution of the mobile phase (50mM KH2PO4) and removed the organic solvent.  
Reducing phosphate buffer concentration did not however solved the precipitation problem, 
thus a 25mM concentration was further tested. Chromatograms obtained with this mobile 
phase are shown in Figure 9. Unfortunately, and despite partially solving the precipitation 
problem, the resolution of the peaks was compromised (Figure 7 and Figure 9). Using this 
mobile phase, and testing standard solutions containing both compounds (assay D), a co-
elution phenomenon between 3-NT and Tyr was observed, hindering the analysis of this 
assay.  
The linearity of the methods using KH2PO4 as mobile phase was calculated through linear 
regression and correlation coefficient (Figure 8). The correlation coefficient is used to assess 
the strength of a linear relationship between pairs of variables (Mukaka, 2012). Overall, 
linear regression analysis of the calibration data showed good linear relationship, with 
correlation coefficients extremely close to 1.
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Figure 8. Calibration curves obtained using linear regression analysis for mobile phases composed by KH2PO4.
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The correlation coefficient determined for Tyr analysis using 500mM KH2PO4, 10% MeOH 
(assay A) was slightly lower in comparison with assays B and C. This fact may be partially 
explained by the aforementioned buffer precipitation issue, rendering the results at the end 
of the run not reliable 
2.3.2. Mobile phase: 0.5% CH3COOH:MeOH:H2O  
For mobile phases based on 0.5% CH3COOH:MeOH:H2O, three different proportions of 
these reagents were tested, as shown in Table VIII. The advantage of this mobile phase in 
relation to the previous one is the absence of phosphate buffer on its composition.  
Firstly, we tested 0.5% CH3COOH:MeOH:H2O (29:1:70, v/v) (assay E), which has already 
been used before for 3-NT and Tyr determination by (Kikugawa et al., 2004), although using 
different experimental conditions. Since the analysis time for assay E was about 40 minutes, 
we then proceeded to increase the oven temperature. A temperature increase leads to an 
increase in solute solubility and diffusivity, as well as a decrease in the viscosity of the 
mobile phase. This significantly improves the partition process kinetics and, consequently, 
the peak shape and the column efficiency (Clark, 2004; Roses, Subirats, & Bosch, 2009; 
Zhu, Goodall, & Wren, 2005). Temperature has also a large effect on the thermodynamics 
of the retention process that can leads to a reduction in the running time and selectivity 
(Roses et al., 2009). Running assay F with a temperature of 40ºC allowed to reduce the 
analysis time from 40 to 30 min. Furthermore, it also allowed to obtain an increased 
efficiency, since peaks showed better resolution using these new conditions (Figure 10). 
 
a) b) 
Figure 9. Representative chromatograms of (a) Tyr and (b) 3-NT using mobile phase C 
(25mM KH2PO4). 
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Afterwards, we tested 0.5% CH3COOH:MeOH:H2O (30:0:70, v/v)  (assays G and H). This 
mobile phase has the advantage of not making use of an organic solvent, rendering it an 
example of "green" liquid chromatographic analysis. Other researchers have already chosen 
similar strategies, namely mobile phases containing the nonionic surfactant Brij-35 instead 
of using an organic solvent (Fernandez-Navarro, Ruiz-Angel, & Garcia-Alvarez-Coque, 
2012). Since the analysis time of assay G was 40 minutes, we decided to follow the previous 
approach and proceed to increase the oven temperature to 40ºC (assay H). The analysis time 
was reduced to 35 minutes, although the resolution of the 3-NT peaks was the lowest among 
all tested proportions (Figure 11).  
 
   
a) 
Figure 10. Representative chromatograms of (a) Tyr and (b) 3-NT using mobile phase F 
(0.5% CH3COOH:MeOH:H2O (29:1:70, v/v)). 
b) 
Figure 11. Representative chromatogram of (a) Tyr and (b) 3-NT analysis using mobile phase H 
(0.5% CH3COOH:MeOH:H2O (30:0:70,v/v)). 
a) 
b) 
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The other proportion tested was 0.5% CH3COOH:MeOH:H2O (15:15:70, v/v) (assays I and 
J) which analysis time was 15 minutes. Thus reduced analysis time was obtained owing to 
an increase in methanol concentration, which is known to decrease the retention time of 
solutes (Q. Zhang, Feng, Yan, & Da, 1999). Therefore, this reduced analysis time was a 
significant advantage of this mobile phase composition over all the others. On the other hand, 
assay J was performed in a new column, which might have accounted for the increased 
retention time of both 3-NT and Tyr (Table VIII) comparatively with assay I. The increased 
retention times obtained with the new column was likely the result of an unstable column 
packing. Regarding the LoD and LoQ, this proportion exhibited great results, in the order of 
units of nanogram per mililiters, and the lowest time analysis as well (Table VIII). In Figure 
12 is shown a representative chromatogram obtained with assay J, where is possible to 
observe that the peaks shape is narrower in comparison with the other proportions tested.  
According to 96/23/EC directive, retention time in liquid chromatography should not vary 
0.10 minutes within technical replicates (Bartesaghi et al., 2007; European Commission, 
2002), which was the case when these proportions were tested (Table VIII)  
 
 
 
 
 
 
 
 
 
Linear regression analysis of the methods using 0.5% CH3COOH:MeOH:H2O as mobile 
phase also showed good linear relationship, with correlation coefficients very close to 1 
(Figure 13). Nevertheless, the proportion 30:0:70 (v/v) was the one which exhibited the 
lowest correlation coefficient for 3-NT.   
Figure 12. Representative chromatograms of (a) Tyr and (b) 3-NT analysis obtained in assay J 
(0.5% CH3COOH:MeOH:H2O (15:15:70,v/v). 
a) b) 
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2.3.3. Mobile phases comparison and selection  
All mobile phases tested for 3-NT detection and quantification exhibited pros and cons. 
Briefly, and as previously mentioned, KH2PO4-based mobile phases presented as major 
disadvantage the precipitation of potassium phosphate within the HPLC tubing system. For 
this reason, we considered this mobile phase to be not suitable for our purpose. 
Nevertheless, this kind of mobile phases had revealed satisfactory results regarding other 
parameters (Table VIII).  
Conversely, 0.5% CH3COOH:MeOH:H2O mobile phase was not affected by any kind of  
precipitation issue. Regarding the different proportions and oven temperatures tested, the 
proportions 29:1:70 (v/v) and 30:0:70 (v/v) at 25ºC exhibited a long analysis time, as well 
as 3-NT broad peaks. On the other hand, the proportion 15:15:70 showed the best results 
with regards to the different parameters evaluated, as can be seen from Table IX to Table 
XIII. Besides, it also exhibited a good resolution, with narrow peaks for both Tyr and 3-
NT. However, the larger concentration of organic solvent used in this proportion could be 
regarded as a disadvantage from an environmental point of view. As a result, and taking 
into account all the pros and cons, the mobile phase 0.5% CH3COOH:MeOH:H2O 
(15:15:70 (v/v)) was regarded as the most suitable for our purposes. 
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Figure 13. Calibration curves obtained using linear regression analysis for mobile phases composed by 0.5% CH3COOH:MeOH:H2O. 
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Table IX. Validation results for 3-NT quantification at 276 nm 
 
 
 
 
 
Validation 
experiment 
(A) (E) (F) (G) (H) (I) (J) 
Specificity 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference with 
analyte peak 
LoD (ng/mL) 40.38 1.76 0.44 36.97 44.35 0.85 0.93 
LoQ (ng/mL) 122.37 5.32 1.33 112.02 134.40 2.56 2.81 
Linearity 
Co-relation 
coefficient 
0.9998 0.9989 0.9996 0.9820 0.9992 1.000 1.000 
Regression 
equation 
y=2.470x108X-
254293 
y= 4.638x108X-
30946 
y=1.8635x108X-
21842 
y=1.8635x108X-
21842 
y=1.30677x108X-
79582 
y=1.307x108X-
1008 
Y=1.595x108X+ 
10814 
Analysis time 15 40 30 40 35 15 15 
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Table X. Validation results for 3-NT quantification at 356 nm 
 
 
 
  
 
 
Validation 
experiment 
(A) (E) (F) (G) (H) (I) (J) 
Specificity 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
LoD(ng/mL) 87.33 71.32 44.05 36.15 8.46 1.22 5.11 
LoQ(ng/mL) 264.63 216.11 133.48 109.53 25.65 3.71 15.49 
Linearity 
Co-relation 
coefficient 
0.9997 0.9999 0.9999 0.9885 0.9994 0.9996 1.000 
Regression 
equation 
y=1.155x108X-
121751 
y=2.132x107X-
26729 
y=8.059x107X+ 
10638 
y=2.459x107X-
45728 
y=5.508x107X-
2954,1 
y=5.056x107X+ 
4432 
y=7.463 x107X+ 
10721 
Analysis time 15 40 30 40 35 15 15 
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Table XI. Validation results for 3-NT quantification at 215nm 
 
 
 
 
Validation 
experiment 
(A) (E) (F) (G) (H) (I) (J) 
Specificity 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
LoD(ng/mL) 24.22 6.91 0.26 10.60 2.90 0.34 6.09 
LoQ(ng/mL) 73.40 20.93 0.80 32.13 9.67 1.04 18.47 
Linearity 
Co-relation 
coefficient 
0.9998 
 
0.9942 
 
0.9998 0.9863 0.9979 0.9991 0.9998 
Regression 
equation 
y = 5.9142x108X - 
552720 
y = 1.1026x108X- 
103627 
y = 4.2281x108X - 
314 050 
y = 1.2349 x108X - 
248426 
y = 3.1054x108X - 
262515 
y = 2.6398x108X + 
201512 
y = 3.8061x108X + 
72837 
Analysis time 15 40 30 40 35 15 15 
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Table XII. Validation results for Tyr quantification at 215 nm 
 
 
  
 
Validation 
experiment 
(A) (E) (F) (G) (H) (I) (J) 
Specificity 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
LoD (ng/mL) 21.40 0.45 0.17 0.72 0.61 0.10 1.81 
LoQ (ng/mL) 64.84 1.36 0.52 2.18 1.84 0.29 5.49 
Linearity  
Co-relation 
coefficient 
0.99594 0.9977 0.9994 1.000 1.000 0.9998 1.000 
Regression 
equation 
y=1.3020x108X- 
336377 
y = 2.3130x108X+ 
197757 
y =2.2779x108X+ 
22815 
y = 3.1070x108X - 
53886 
y =  3.0565x108X+ 
51242 
y = 4.1258x108X+ 
205922 
y =  2.1995x108+ 
109 070 
Total analysis 
time 
15 40 30 40 35 15 15 
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Table XIII. Validation results for Tyr quantification at 276 nm 
 
 
 
Validation 
experiment 
(A) (E) (F) (G) (H) (I) (J) 
Specificity 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
No interference 
with analyte peak 
LoD (ng/mL) 37.15 0.76 60.85 66.82 1.37 0.26 0.53 
LoQ (ng/mL) 112.58 2.29 184.39 202.50 4.15 0.78 1.60 
Linearity  
Co-relation 
coefficient 
0.9974 0.9878 0.9998 1.000 
 
0.9999 
 
1.000 0.9999 
Regression 
equation 
y =   2.3391x107X- 
55398 
y =  3.5431x107X 
+ 39477 
y = 3.9245x107X 
+ 1065.7 
y = 5.0731x107X -
6355 
y= 4.9759x107X -
13209 
y = 6.7530x107X + 
10086 
y =  3.7935x107X 
+4312,5 
Total analysis 
time 
15 40 30 40 35 15 15 
Biomarkers of Nitrosative Stress. 
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2.3.4. Optimization method  
2.3.4.1.  Optimization of Tyr standard preparation 
One trouble that was present throughout the study was the dissolution of Tyr. For that 
purpose, we tested four different solvents, as shown in Figure 14 . Dissolving Tyr in the 
selected mobile phase (0.5% CH3COOH:MeOH:H2O 15:15:70, v/v) using a water bath 
between 40-50ºC for 15 min ended up being the most effective way. Conversely, and 
regarding the acidified water, some chromatograms obtained showed nonspecific peaks. 
Moreover, the use of ultrapure water was not efficient since insoluble crystalline particles 
were observed after dissolution. Lastly, the main drawback of using PBS is that its pH (7.35) 
is different from the pH of the selected mobile phase (3.10).  
Optimization of the solubility of Tyrosine
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Figure 14.  Comparison of the solvents using for Tyr dissolved. 
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2.3.4.2. Optimization of the temperature 
Regarding the temperature of the method, a wide range (15, 20, 25, 35, 45, 55 and 65ºC) was 
assayed while maintaining the conditions of other parameters. When temperatures from 35 
to 65ºC, with detection at 215 and 276 nm, were tested, a 3-NT non-specific peak was 
obtained. A similar phenomenon was observed when testing at 15ºC. Temperatures between 
20 and 25ºC showed to be specific for 3-NT, with detection at 276 nm and 356 nm. 
Furthermore, and in order to obtain a higher peak resolution, running the assays at 20ºC with 
a flow rate of 1.2 mL/min is advisable. 
2.3.5. Method Validation  
2.3.5.1.  Specificity 
A specific 3-NT quantification method should have the ability to detect 3-NT unequivocally 
without any interference from tyrosine or other close structural relatives (Tsikas & Duncan, 
2014). In order to determine the specificity of the developed method in all assays, 3-NT and 
Tyr were spiked into different biological matrices (more details can be found in Chapter III). 
The method was specific for 3-NT with detection at 356 nm for all biological matrices. 
However, when quantification was carried out at 215 or 276 nm in whole blood, other 
unknown molecules were also present in the 3-NT peak. Consequently, these wavelengths 
are not recommended for 3-NT quantification in whole blood using this method. 
2.3.5.2.  Linearity, LoD and LoQ 
Table XIV lists the linearity parameters of the calibration curves for 3-NT (and Tyr). The 
LoD and LoQ are also given in this table.  
Table XIV. Linearity, retention time, LoD and LoQ 
 3-NT (ʎ=215nm) 3-NT (ʎ=276nm) 3-NT (ʎ=356nm) Tyr (ʎ=215nm) Tyr (ʎ=276nm) 
LoD (ng/mL) 0.655 0.367 1.862 0.213 1.380 
LoQ (ng/mL) 2.184 1.113 5.642 0.645 4.182 
Retention 
Time 
(min ± sd) 
10.164 ± 0.054 10.164 ± 0.053 10.165 ± 0.053 4.278 ± 0.020 4.278 ± 0.020 
Linearity 
Co-relation 
coefficient 
1.000 1.000 0.999 1.000 0.999 
Regression 
equation 
y = 7.0805x108x -
7475.6 
y = 2.5134x108x + 
25707 
y = 1.1970x108x + 
10814 
y = 1x108x + 
7175.6 
y = 3x107x + 
586.64 
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2.3.5.3.  Accuracy - recovery rate  
The accuracy of an analytical method is defined as the proximity of the mean concentration 
determined by the analytical method to the true concentration of the analyte (Hui et al., 
2012). Table XV presents the results of accuracy determined from standard solutions. The 
inaccuracy varied from 0.007 to -6.26%. Samples with the highest or lowest 3-NT 
concentrations (close to LoQ) were those which exhibited a higher relative error (RE). 
According to the literature, the RE mean value should be within 15% of the nominal value 
(Sonawane et al., 2014), which was the case of this method.  
Table XV. Analytical results of accuracy test by standard solutions  
Table XVI shows the results expressed as percent recoveries of 3-NT in serum samples. 
Regarding detection at 356 nm and 276 nm, the recovery value ranged from 90.92 to 113.12 
%, and RE values varied between 0.99 to 13.12%. The concentrations obtained were 
relatively close to the known concentrations, with RE or inaccuracy not greater than 13.12% 
in all cases, which is in accordance with the previous mentioned RE limit (<15%) (Sonawane 
 
Wavelength (nm) Concentration (ng/mL) REa  (%) No. of samples 
356 
50000 0.007 6 
25000 -3.49 6 
10000 0.51 6 
5000 -0.52 6 
2500 0.72 6 
1250 0.16 6 
625 -2.32 6 
312.5 -0.83 6 
276 
50000 -0.08 6 
25000 -3.05 6 
10000 0.24 6 
5000 -0.82 6 
2500 0.16 6 
1250 0.30 6 
625 -2.79 6 
312.5 -3.82 6 
215 
50000 0.12 6 
25000 -3.33 6 
10000 0.44 6 
5000 0.28 6 
2500 -0.03 6 
1250 1.88 6 
625 -3.31 6 
312.5 -6.26 6 
a)Relative error (RE) is derived by using the following equation: Relative error % = ((Mean cal. conc. - True conc.)/True 
conc.) × 100%. 
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et al., 2014). Concerning detection at 215 nm, inaccuracy was greater than 15% (79.62%), 
thereby not validated for this parameter.  
Table XVI. Analytical results for accuracy test from serum sample 
2.3.5.4. Precision 
Intra-day precision was assessed by standard solutions (50000, 25000, 10000, 5000, 2500, 
12500, 625, 312.5 ng/mL) as well as by spiking different commercial human serum samples 
with three different 3-NT concentrations (25000, 1000, 50 ng/mL). The precision of a 
bioanalytical method for each concentration level should be < 15% of relative standard 
deviation (RSD) or coefficient of variation (Sonawane et al., 2014). The precision of our 
method, which was determined using FDA guidelines for bioanalytical method validation 
(FDA, 2013), was 2.23% and 6.75% below the RSD for all standard solutions and serum 
samples, respectively (Table XVII and Table XVIII). 
Table XVII. Analytical results for repeatability (intraday test) from standard solutions  
Wavelength 
(nm) 
Spiked 
Concentration 
(ng/mL) 
Measured 
Concentration 
(ng/mL) 
REa  
(%) 
Recovery 
(%) 
No. of 
samples* 
356 
25000 23067,3 -7,73 92,27 6  
1000 910,7 -8,93 91,07 6 
50 50,5 0,99 100,99 6 
276 
25000 24519,8 -1,92 98,08 6 
1000 909,2 -9,08 90,92 6 
50 56,6 13,12 113,12 6 
215 
25000 21360 -14,56 85,44 6 
1000 848 -15,20 84,80 6 
50 90 79,62 179,62 6 
a)Relative error (RE) is derived by using equation: Relative error % =([Mean cal. conc.] – [True conc.])/[True conc.] × 100%. 
*Each sample performed in triplicated. 
Wavelength (nm) Concentration (ng/mL) RSD (%) No. of samples 
356 
50000 0.7 6 
25000 0.23 6 
10000 0.76 6 
5000 0.97 6 
2500 1.87 6 
1250 0.72 6 
625 2.23 6 
312.5 1.37 6 
Biomarkers of Nitrosative Stress. 
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Table XVIII.  Analytical results for repeatability (intraday test) from serum samples 
 
2.4. Conclusions  
After a deep analysis of the results obtained with all the mobile phases tested, the best results 
were obtained using 0.5% CH3COOH:MeOH (15:15:70 (v/v)), at 25ºC, flow rate of 1 
mL/min, and with detection at wavelengths 215, 276 and 356 nm. By using this protocol, it 
was possible to obtain a linear calibration curve (correlation coefficient = 1), LOD/ LOQ in 
Table XVII. (continued) 
Wavelength (nm) Concentration (ng/mL) RSD (%) No. of samples 
276 
50000 1.26 6 
25000 0.16 6 
10000 0.56 6 
5000 0.54 6 
2500 0.62 6 
1250 0.88 6 
625 1.14 6 
312.5 2.03 6 
215 
50000 0.87 6 
25000 0.76 6 
10000 0.58 6 
5000 1.08 6 
2500 0.54 6 
1250 1.38 6 
625 1.36 6 
312.5 0.72 6 
Wavelength (nm) Concentration (ng/mL) RSD (%)a No. of samples* 
356 
25000 0.40 6 
1000 2.15 6 
50 2.93 6 
276 
25000 0.97 6 
1000 1.15 6 
50 6.75 6 
215 
25000 1,22 6 
1000 3,60 6 
50 4,75 6 
a Relative standard deviation is derived by using equation: RDS  % = (standard deviation )/(mean peak  
area) × 100%. 
*Each sample performed in triplicated.  
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the order of units ng/ml, and a reduced analysis time per sample (15 minutes). Moreover, 
and most importantly, the developed method exhibited a good specificity, with no 
interference observed with 3-NT structural relatives, namely Tyr. Lastly, the method 
revealed good precision and accuracy.
  
 
 
  
  
 
 
 
Chapter III         
Applicability of the developed method for 3-nitrotyrosine quantification 
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3.1. Introduction  
Most of 3-NT quantification methods developed throughout the last years have been applied 
in several biological matrices, such as biological tissues and fluids (plasma, serum, urine, 
cerebrospinal fluid, synovial fluid, etc.) (Radabaugh et al., 2008; Ryberg & Caidahl, 2007). 
The human plasma and serum are of special interest since they are widely used among 
clinical and biological studies (Yu et al., 2011). Furthermore, serum has been reported has 
showing higher sensitivity in biomarker detection, which is likely explained by the globally 
higher metabolite concentrations in serum than in plasma (Yu et al., 2011).   
On the other hand, urine has also been tested in biomarker research. Although it offers the 
possibility of a non-invasive measurement, these biological matrices are often referred to as 
giving rise to unreliable results (Ryberg & Caidahl, 2007). Regarding this, Misko et al. 
(2013) measured 3-NT levels in different biological matrices (urine, plasma and synovial 
fluid), demonstrating that urine exhibited different results in relation to the others samples 
tested. 
3-NT is ubiquitous in a wide range of biological samples, although each type of biological 
sample has different basal concentrations (Tsikas & Duncan, 2014). Depending on the 
biological sample, and according to the literature, the normal concentrations found in healthy 
individuals may vary. Table XIX shows the 3-NT concentration range usually found in both 
healthy and pathological states, as determined by different methods and biological samples.  
3.1.1. Aim  
Chapter III briefly describes the various biological samples that can be used for 3-NT 
quantification. The aim was to evaluate the performance of an HPLC-based protocol for 3-
NT quantification (described in Chapter II) in a wide range of biological matrices, namely 
(i) serum, (ii) urine, (iii) whole blood, (iv) B16 F-10 melanoma cell line, (v) growth medium 
conditioned with the same cell line, (vi) gram-negative (Escherichia coli) and (vii) gram 
positive (Staphylococcus aureus) bacterial and (viii) yeast (Saccharomyces cerevisiae)  
suspensions. 
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Table XIX. 3-NT concentration ranges found in different biological samples from both healthy and pathological states, as determined by different methodologies 
Reference Sample (mean age ± years) Biological sample Method Concentration 3-NT 
Söderling et al. (2003) 
12 healthy non-smoking 
volunteers (43±9) 
Plasma GC/NCI-MS/MS 0.74 ±  0.31 nM* 
Tsikas et al. (2003) 
10 healthy volunteers (51±10) Plasma GC tandem MS 1.149 ± 0.73 nM* 
6 healthy volunteers (25±3) Plasma GC tandem MS 2.677 ± 1.540nM* 
10 healthy volunteers (51±10) Plasma GC-MS 4.46 ± 4.49 nM* 
6 healthy volunteers (25±3) Plasma GC-MS 5.447 ± 2.783nM* 
W.-Z. Zhang et al. (2007) 
20 healthy non-smoking 
volunteers (41.2) 
Plasma LC-MS/MS 4.54 ± 2.75 nM* 
18 healthy smokers (42.0) Plasma LC-MS/MS 17.42 ± 11.6 nM* 
Radabaugh et al. (2008) 40 healthy volunteers Plasma LC–MS/MS 224–962 pg/mL (0.99-4.2 nM)# 
Misko et al. (2013) 
143 healthy volunteers Plasma 
Immunoaffinity two-dimensional 
LC-MS/MS 
536.4 pg/mL (2.49nM)# 
174 osteoarthritis patients Plasma 
Immunoaffinity two-dimensional 
LC-MS/MS 
704.1 pg/mL (3.11nM) # 
Pourfarzam et al. (2013) 
50 patients with no history of 
cardiac diseases (58.9 ± 10.3) 
Plasma 
HPLC-fluorescence detector  470 
nm 
4.4 ± 1.8 nM* 
50 stable CAD patients  
(61.2 ± 11.23) 
Plasma 
HPLC-fluorescence detector  470 
nm 
12.8 ± 3.9 nM* 
50 unstable CAD patients  
(59.9 ± 10.45) 
Plasma 
HPLC-fluorescence detector  470 
nm 
14.8 ± 4.8 nM* 
Sun et al. (2007) 70  healthy  Chinese volunteers Plasma Sandwich ELISA 7.9±7 nmol/L# 
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Table XIX. (continued)  
Reference Sample (mean age ± years) Biological sample Method Concentration 3-NT 
Radabaugh et al. (2008) 131 healthy volunteers Serum LC–MS/MS 179–1540 pg/mL (0.79 - 6.8 nM)# 
F. Khan et al. (2006) 
25 non-smoking healthy female 
volunteers (age 24–50) 
Serum Sandwich ELISA 1.1 ± 0.81 µM# 
24 systemic lupus erythematosus 
patients (age 18–50) 
Serum Sandwich ELISA 96.52 ± 21.12 µM# 
Tsikas et al. (2005) 10 healthy volunteers (36.5 ± 7.2) Urine GC–tandem MS 8.4 ± 10.4 nM 
Radabaugh et al. (2008) 8 healthy volunteers Urine LC–MS/MS 63.5–751 pg/mL (0.28-3.32nM)# 
Ryberg et al. (2004) 
19 patients without history or 
symptoms/ signs of 
psychiatric, neurological, 
malignant or systemic disorders 
Cerebrospinal fluid GC/NCI-MS/MS 0.35 ± 0.019 nM* 
17 Alzheimer’s disease  patients Cerebrospinal fluid GC/NCI-MS/MS 0.44 ± 0.031 nM* 
14 amyotrophic lateral sclerosis 
patients 
Cerebrospinal fluid GC/NCI-MS/MS 0.38± 0.034 nM* 
Radabaugh et al. (2008) 35 healthy volunteers Cerebrospinal fluid LC–MS/MS 335–5730 pg/mL (1.48-25.33nM)# 
Seven, Aslan, Incir, and 
Altintas (2013) 
15 volunteers with normal 
pressure hydrocephalia 
Cerebrospinal fluid ELISA based on the sandwich 573.54 ± 142.86 nM 
Seven et al. (2013) 
20 relapsing remitting multiple 
sclerosis  patients before methyl 
prednisolone therapy 
Cerebrospinal fluid ELISA based on the sandwich 927.89 ± 244.84 nM 
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Table XIX. (continued) 
Reference Sample (mean age ± years) Biological sample Method Concentration 3-NT 
Lärstad et al. (2005) 
10 healthy subjects (46 ± 2.6) Exhaled breath condensate GC/NICI/ tandem MS 31 pM* 
8 asthma patients (49 ± 5.1) Exhaled breath condensate GC/NICI/ tandem MS 31pM* 
Radabaugh et al. (2008) 40 healthy volunteers Synovial fluid LC–MS/MS 54.4–822 pg/mL (0.24-3.63nM)# 
Ueshima et al. (2007) 
5 chronic obstructive pulmonary 
disease patients (71.6 ± 2.4) 
Sputum HPLC-ECD 0.55 ± 0.15 pmol/mL# 
5 chronic obstructive pulmonary 
disease patients (71.6 ± 2.4) 
Saliva HPLC-ECD 0.02 ± 0.01 pmol/mL# 
* Free 3-NT; # Total 3-NT 
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3.2. Material and Methods  
3.2.1. Instrument and software 
As described in 2.2.1.  
3.2.2. Reagents and consumables  
As described in 2.2.2. 
3.2.3. Analytical procedure  
3.2.3.1. Mobile phase  
0.5% CH3COOH:MeOH:H2O solutions were prepared according to the proportion 15:15:70 
and filtered through a 0.45 µm membrane. 
3.2.3.2. Calibration standards  
0.5 mg/mL 3-NT and Tyr stock solutions were made using the mobile phase previously 
mentioned. All stock solutions were filtered through a filter membrane device. The first 
assays were performed using separate 3-NT and Tyr standard solutions in the following 
concentrations (50000; 25000; 10000; 5000; 2500; 1250; 625 and 312,5 ng/mL). Standard 
solutions were prepared by diluting the respective stock solution into the mobile phase. 
When required, warm was used in order to better dissolve the reagents. These standard 
solutions were used for calibration purposes.  
3.2.3.3.  Sample preparation: serum, urine, and whole blood 
The biological samples tested in this chapter are described in Table XX. All samples were 
initially submitted to a previously published protocol in order to precipitate proteins 
(Peixoto, 2012). Briefly, 1mL of 15% TFA (freshly prepared) was added to 1mL of each 
sample, and then vortexed for 20 seconds. Afterwards, samples were centrifuged at 8000 rcf 
during 10 min. The supernatant was then extracted and a new centrifugation was performed 
in order to pellet any remaining protein precipitates. Lastly, the obtained supernatants were 
filtered through a filter membrane device, and spiked with three different concentration 
levels of either 3-NT or Tyr (50, 1000, and 25000 ng/mL). Non-spiked supernatants were 
simultaneously tested.  
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Table XX. List of the biological matrices used to evaluate the applicability of the developed method 
 
3.2.3.4.  Sample preparation: B16 F10 melanoma cell line and conditioned growth 
medium  
B16 F10 murine (ATCC, No CRL®-6475) melanoma cell line was obtained from American 
Type Culture Collection (ATCC) and cultured in MEM supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco, Portugal), 1% penicillin/ streptomycin (Gibco) 
and 1% non-essential aminoacids (Gibco). Cells were grown at 37ºC in a humidified 5% 
CO2 atmosphere. B16 cells were tested at concentration 1x10
4 cells/mL. Cells stored at -
80ºC were initially submitted to a defrosting/freezing/defrosting cycle (15 min. each), 
followed by sonication for 10 min using two different systems: (A) Silent Crusher S 
(Heidolph Instruments GmbH & Co. KG, Germany), and (B) Bandelin Sonorex RK 100  
(Sigma-Aldrich®, Portugal), at 47-63 Hz and 35 kHz, respectively. Afterwards, samples 
were prepared as previously described in 3.2.3.3. Regarding this, 15% TFA was added prior 
(A1 and B1) or after (A2 and B2) the sonication step in order to assess the most suitable 
protocol. The medium used for cell growth (MEM, conditioned medium) was also tested for 
3-NT quantification, thus the same protocols for protein precipitation were also applied. 
Samples spiked with 25000 ng/mL of 3-NT were also tested. 
Sample 
ID 
Company Reference Designation Biological sample 
A Cormay 5-172 Cormay serum HN Human serum 
B Cormay 5-173 Cormay serum HP Human serum 
C Human 13951 
Serodo Universal control serum for 
Clinical Chemistry assayed 
Human serum 
D Cormay 5-174 Cormay multicalibrator level 1 Human serum 
E Randox UE  1557 Human precision control - level 2 Human serum 
F Randox UE  1558 Human precision control - level 3 Human serum 
G HOSLAB n/a HD normal control Human serum 
H Cormay 5-161 Cormay urine control level 1 Human urine 
I Cormay 5-162 Cormay urine control level 2 Human urine 
J Randox SD 126 RANSOD 
Bovine-based 
whole blood 
K Randox SC 692 RANDEL 
Bovine-based 
whole blood 
n/a, not applicable 
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3.2.3.5. Sample preparation: bacterial and yeast suspensions 
Gram-positive S. aureus (ATCC® 25923) and gram-negative E. coli (ATCC® 25922) 
bacteria, as well as the yeast S. cerevisiae were tested. Bacteria were inoculated into 
trypticase soy agar (TSA,VWR Chemicals Prolabo, Portugal), whereas yeast was inoculated 
into yeast extract peptone dextrose (YPD, VWR). Cultures were then incubated overnight at 
37ºC and adjusted to an optical density (OD) at 620 nm of 0.2 using sterile ultrapure water. 
Subsequently, cells were sonicated for 10 min (Silent Crusher S at 47-63 Hz). Afterwards, 
proteins were precipitated as described in 3.2.3.3. Samples spiked with 25000 ng/mL of 3-
NT were also tested. 
3.2.3.6. Recovery rate  
In order to assess whether the protein precipitation protocol affects the recovery rate of the 
developed method, a random serum sample was spiked with 25000 ng/mL of 3-NT prior or 
after the protein precipitation protocol has been applied. A non-spiked serum sample was 
use as control. Assays were performed twice, with technical triplicates.  
3.2.3.7. Chromatographic conditions  
The chromatographic conditions used were the same as described in 2.2.3.4. 
3.2.4. Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 6.02 (La Jolla, CA, USA). 
Calibration curves/ equations were obtained using linear regression analysis. 
3.3. Results and discussion  
The purpose of this chapter was to assess which biological matrices are suitable for 3-NT 
quantification with our developed method, producing reliable results. Hence, a wide variety 
of samples was tested, ranging from human-associated matrices to microbial suspensions. 
A common approach for 3-NT quantification is the prior cleavage of peptide bonds in order 
to release the free amino acids from proteins in fluids or tissues. This cleavage may be 
achieved by acid hydrolysis or enzymatic digestion (Delatour et al., 2007; Radabaugh et al., 
2008; Tsikas, 2012). Delatour et al. (2007) compared both methods in terms of the reliability 
of the 3-NT measurement, providing evidence that acid hydrolysis leads to more reliable 
results. However, Radabaugh et al. (2008) pointed out that a prior acid hydrolysis step is 
more prone to artifact formation in comparison with enzymatic digestion. In fact, a concern 
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about 3-NT quantification residues in proteins is that the measurement of this Tyr nitration 
product may be subjected to artifacts and/or incomplete digestion of proteins. 
Vivekanandan-Giri, Byun, and Pennathur (2011) applied a protein precipitation protocol 
based on the addition of 10% trichloroacetic acid (final concentration) followed by a 
centrifugation step (3000g for 10 min), which is similar to the protocol used in this work. 
The protocol used in this work for protein precipitation was previously optimized by our 
group (Peixoto, 2012), providing evidence that 15% TFA is the optimum concentration for 
this kind of application. Moreover, the TFA solution should be prepared right before 
analysis, since older solutions may lead to erroneous results.  
 
3.3.1. Serum, urine and whole blood 
In this phase, several biological matrices from quality control samples were tested, such as 
serum, urine and whole blood. The linearity was determined for all the assays ( Table XXI). 
Each sample was spiked with three different 3-NT concentrations and a quantitative analysis 
was performed.  
 Table XXI. Linearity results obtained for all assays 
  
3.3.1.1. Serum 
As stated above, serum is one of the most tested biological matrices in routine diagnosis (Yu 
et al., 2011). The results drawn from this study revealed that 3-NT can be reliably quantified 
in serum samples, even when present at very high or low concentrations (Table XXII).  
 
Linearity  
3-NT 
(ʎ=215nm) 
3-NT 
(ʎ=276nm) 
3-NT 
(ʎ=356nm) 
Try 
(ʎ=215nm) 
Try 
(ʎ=276nm) 
Co-relation 
coefficient 
1.000 0.9997 0.9998 0.9997 0.9999 
Regression 
equation 
y =6.0545x108x 
-9563.5 
y =2.33 x108x + 
7823.4  
y =1.10x108x - 
2769,7  
y =1.78x108x -
9205.5 
y = 3.89x107x 
+8569.7 
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Table XXII. 3-NT concentrations obtained in serum spiked-samples 
Sample_spiked 
concentration (ng/mL)    
3-NT concentration 
ng/mL (356nm)           
3-NT concentration 
ng/mL (276nm) 
3-NT concentration 
ng/mL (215nm) 
A_25000 22328 26070 22151 
A_1000 1035 897 1014 
A_50 84 84 216 
A_0 28 39 16 
B_25000 24403 24151 28619 
B_1000 799 973 1796 
B_50 83 198 1078 
B_0 29 39 17 
C_25000 22536 24324 20737 
C_1000 955 975 847 
C_50 82 75 94 
C_0 31 41 16 
D_25000 23258 24566 21509 
D_1000 911 943 812 
D_50 65 78 55 
D_0 43 54 30 
E_25000 23412 25026 21582 
E_1000 990 1017 843 
E_50 96 88 140 
E_0 32 40 19 
F_25000 22658 23538 20598 
F_1000 966 958 833 
F_50 80 66 46 
F_0 29 40 25 
G_25000 23512 24723 21704 
G_1000 939 961 860 
G_50 74 73 82 
G_0 29 39 16 
 
Moreover, it was possible to detect 3-NT at the three different wavelengths (215, 276 and 
356 nm) in all serums samples. As previously stated in Chapter II, 3-NT quantification at 
215 nm showed not good accuracy (RE >15%). With regards to the extraction efficiency in 
serum samples, the mean recovery rates were 94.31±4.43% at 356 nm, 100.46±9.81% at 276 
nm, and 214.92±209.76% at 215 nm. Figure 15 exhibits a representative chromatogram of a 
serum sample.  
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3.3.1.2. Urine  
Similarly to that observed for serum, a reliable 3-NT quantification was also possible in urine 
samples (Table XXIII). Urine is a biological sample with special characteristics, particularly 
its acidic nature, which is associated with 3-NT artefact formation (Mergola et al., 2013). 
Nevertheless, Mergola et al. (2013) have found a good 3-NT recovery rate (95%), especially 
in urine samples from patients with neurological diseases where low concentrations are 
usually found. Concerning the extraction efficiency in urine samples, the mean recovery 
rates were 95.03±5.12% at 356 nm, 97.93±23.51% at 276 nm, and 198.32±195.32 at 215 
nm. The recovery rate at 215 nm was due to the extremely high recovery rate observed for 
spiked-samples with 50 ng/mL 3-NT (423.65±373.12%). Representative chromatograms of 
a 3-NT-spiked urine sample with detection at 276 and 356 nm are shown in Figure 16 and 
Figure 17 , respectively.  
Overall, the recovery rates observed for serum and urine were > 90% (356 and 276nm).  
 
 
 
 
3-NT 
Figure 15. Representative chromatogram of a 3-NT-spiked serum sample (detection 276 nm). 
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Figure 16. Representative chromatogram of a 3-NT-spiked urine sample (detection at 276 nm). 
Figure 17. Representative chromatogram of a 3-NT-spiked urine sample (detection at 356 nm). 
3-NT 
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Table XXIII. 3-NT concentrations obtained in urine spiked-samples 
 
3.3.1.3. Whole blood 
Besides serum and urine, this study has also shown that 3-NT quantification is possible in a 
biological matrix like whole blood (Table XXIV). However, and contrary to that observed 
for all serum and urine samples, which detection was possible at three different wavelengths, 
detection in whole blood was possible only at 356 nm (Figure 18). Nevertheless, and as 
previously reported by Herce-Pagliai et al. (1998), 356 nm is the most specific wavelength 
for 3-NT detection (Figure 18 – c) and d)). Therefore, the mobile phase developed and 
validated in this study is suitable for 3-NT quantification in the three different sample types 
(serum, urine, and whole blood), with detection at 356 nm. On the other hand, Tyr 
quantification in whole blood was not possible, since an impure chromatographic peak for 
Tyr was observed in most cases.  
Regarding whole blood, the recovery rates at 356nm were 88.82±7.47% for 25000ng/mL, 
87.19±2.08% for 1000ng/mL, and 64.43±0.87% for 50ng/mL.  
Table XXIV. 3-NT concentrations obtained in whole blood spiked-samples; n/a not applicable 
Sample_spiked 
concentration (ng/mL) 
3-NT concentration 
ng/mL (356nm)           
3-NT concentration 
ng/mL (276nm) 
3-NT concentration 
ng/mL (215nm) 
H_25000 22794 23132 20437 
H_1000 937 771 762 
H_50 74 46 96 
H_0 31 39 16 
I_25000 23151 23042 20669 
I_1000 974 864 1050 
I_50 90 156 361 
I_0 33 39 17 
Sample_spiked 
concentration (ng/mL) 
3-NT concentration 
ng/mL (356nm) 
3-NT concentration 
ng/mL (276nm) 
3-NT concentration 
ng/mL (215nm) 
J_25000 23556 n/a  n/a.  
J_1000 916 n/a. n/a. 
J_50 62 n/a. n/a. 
J_0 29 n/a. n/a. 
K_25000 20914 n/a.  n/a.  
K_1000 887 n/a. n/a. 
K_50 62 n/a. n/a. 
K_0 30 n/a. n/a. 
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3.3.2. Other biological matrices 
In order to evaluate the applicability of the developed method in other biological matrices, 
we evaluated 3-NT detection/quantification in i) B16 F-10 melanoma cell line, ii) growth 
medium conditioned with the same cell line, iii) gram-negative (E. coli) and gram positive 
(S. aureus) bacterial and iv) yeast (S. cerevisiae)  suspensions.  
3.3.2.1. Melanoma cell line and growth medium conditioned 
Human melanoma cells express iNOS which is responsible for induced NO-based immune 
response. The expression of this molecule is associated with poor survival of patients with 
melanoma, thereby iNOS is a molecular marker of poor prognosis and a possible target for 
therapy (De Sanctis et al., 2014; Grimm, Ellerhorst, & Ekmekcioglu, 2008). On the other 
hand, a significant association between iNOS expression and 3-NT production has been 
3-NT 
c) d) 
Figure 18. Representative chromatograms of a 3-NT-spiked whole blood sample with detection at a) 
and c) 276 nm and b) 356 nm and d) non-spiked whole blood sample (detection at 276 nm) 
a) b) 
3-NT 
3-NT 
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found in melanoma patients, using immunohistochemistry detection (Grimm et al., 2008; 
Winkler, Koedel, Kastenbauer, & Pfister, 2001). Therefore, the applicability of the 
developed method in these type of cell lines was also evaluated.  
In this study, B16 F10 melanoma cell line (Figure 19) was tested, since it is widely used in 
a variety of studies, and is also associated with high metastatic activity (Herlyn & Fukunaga-
Kalabis, 2010). This cell line (at a concentration of ~104 cells/mL), as well as the medium 
used for cell growth (Figure 20), were spiked with the same 3-NT concentration (25000 
ng/mL). 
 
 
 
 
 
 
 
 
  
 
 
3-NT 
Figure 19. Representative chromatogram of a 3-NT-spiked B16 F10 melanoma cell line sample 
(detection at 276 nm). 
Figure 20. Representative chromatogram of a 3-NT-spiked growth medium conditioned sample 
(detection at 276 nm). 
3-NT 
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3.3.2.1.1. Optimization of cell lysis and protein precipitation 
Since human cells are difficult to disrupt, four different sonication-based protocols for cell 
lysis and protein precipitation were applied to B16 F-10 melanoma cell line, as well as to 
the medium used for their growth (conditioned medium). Cellular lysis through sonication 
is an effective way for the recovery of periplasmic, membrane-bound, or insoluble 
recombinant proteins (Bystryak, Santockyte, & Peshkovsky, 2015). Moreover, sonication 
systems are usually rapid and easy-to-use. Overall, protocols B1 and B2 provided better 
results, although protocol B2 (sonication with ultrasound bath followed by addition of 15% 
TFA) was superior (Figure 21). The differences between the results originated by the two 
sonication systems was likely to be due to the frequency used.  
 
3.3.2.2. Bacterial and yeast suspensions 
Besides human biological matrices, the developed protocol was also tested for 3-NT 
quantification in bacterial and yeast suspensions, which was also successful (Figure 22 and 
23). Therefore, this study provides evidence that the developed method may also be applied 
to different fields other than human biology, for instance in microbial research.   
The same protocol used for B16 F-10 melanoma cell line and growth medium (sonication-
based method) was also applied to bacterial and yeast suspensions, since several studies has 
claimed that sonication for 10 min is effective to achieve bacterial cells lysis  (Joyce, Al-
Hashimi, & Mason, 2011; Monsen, Lövgren, Widerström, & Wallinder, 2009).  
Figure 21. Results obtained using the different cell lysis and protein precipitation protocols. 
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Furthermore, bacterial and yeast suspensions were made with ultrapure water, allowing cell 
wall disruption. Figure 24, 25 and 26 show representative chromatograms of 3-NT-spiked 
bacterial and yeast suspensions.  
.
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Figure 22. 3-NT quantification in 3-NT spiked bacterial suspensions. 
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Figure 23. 3-NT quantification in 3-NT-spiked yeast suspensions. 
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3-NT 
Figure 25. Representative chromatogram of a 3-NT-spiked gram negative bacterial 
suspensions sample (detection at 276 nm). 
3-NT 
Figure 24. Representative chromatogram of a 3-NT-spiked gram positive bacterial 
suspensions sample (detection at 276 nm). 
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3.3.3. Influence of protein precipitation protocol on recovery rates 
The recovery rates using a random serum sample spiked with 25000 ng/mL of 3-NT were 
calculated in order to assess the degree of analyte loss when the protein precipitation protocol 
is applied. Overall, the recovery rates obtained for samples spiked before and after the 
protocol has been applied were fairly similar (about 1% difference between them). This is 
indicative that such protocol does not lead to a significant loss of 3-NT and, as a result, does 
not compromise the accuracy of the results.  
3.4. Conclusion  
The protocol used (0.5% CH3COOH:MeOH:H2O 15:15:70 (v/v) as the mobile phase with 
detection at 356  nm), allowed the successful 3-NT detection and quantification in all 
biological matrices tested. Whole blood was the only biological matrix which 3-NT detection 
and quantification at 276 nm and 215 nm was not possible. Nevertheless, and unlike other 
previously described methods for 3-NT quantification, our HPLC-based method was 
successfully applied to a wide range of biological matrices, exhibiting a great performance 
in all of them. 
Figure 26. Representative chromatogram of a 3-NT-spiked yeast suspension sample 
(detection at 276 nm). 
3-NT 
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Chapter IV  
Main conclusions and future directions
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4.1. Main conclusions  
Research on 3-NT has been focusing on its use as biomarker of oxidative/nitrosative stress 
in wide range the pathologies. In another research line, 3-NT has also been proposed as a 
target for therapeutic interventions in pathologies involving oxidative stress (Joly & 
Grunfeld, 2014).  
Recognising the potential use of 3-NT as a tool for diagnosis and/ or treatment monitoring 
of several pathological conditions, we developed a simple, fast, and cost-effective HPLC-
based method, and validated it at the level of specificity, linearity, LoD and LoQ, accuracy 
and precision. Considering the availability of HPLC equipment in a wide range of laboratory 
settings nowadays, as is the case of clinical biochemistry laboratories, we chose this 
methodology as the base for our method development process.   
The first step of this study was the evaluation of different mobile phases in the detection and 
quantification of 3-NT. The KH2PO4-based mobile phases have presented the disadvantage 
of precipitation of potassium phosphate as opposed to 0.5% CH3COOH:MeOH:H2O-based 
mobile phase. Regarding the three concentrations of 0.5% CH3COOH:MeOH:H2O tested, 
the proportion 15:15:70 showed the best results and chromatograms exhibited well defined 
peaks. In this sense, mobile phase 0.5% CH3COOH:MeOH:H2O (15:15:70 (v/v)) was 
regarded as the most suitable for our purposes. 
The second step relied on the optimization and further validation of the selected method, 
which exhibited a good specificity, precision, accuracy and linearity. Moreover, LOD/ LOQ 
were in the order of units ng/mL, and the analysis time per sample was about 15 minutes.  
The next step was to evaluate the applicability of such method in different biological 
samples. Firstly, we evaluated its performance in the most tested biological matrices in 
clinical biochemistry laboratories, namely serum, urine, and whole blood. Regarding this, 
the method allowed the successful detection and quantification of 3-NT at 356 nm, although 
accurate quantification in serum and urine was also possible at other wavelengths (215 and 
276 nm). Additionally, and for the sake of increasing the applicability of the method, other 
biological matrices were tested, namely B16 F-10 melanoma cell line and respective 
conditioned medium, as well as bacterial and yeast suspensions. Again, detection and 
quantification of 3-NT was also successful at the aforementioned wavelengths. Up to date, 
and as far as we know, there is no published work describing 3-NT quantification methods 
the previous biological matrices by using HPLC or other chromatographic equipment. 
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Therefore, and besides the applicability of our method for clinical purposes, we gathered 
evidence in the present study that it might also be used for scientific research purposes, 
particularly, in the field of oxidative/ nitrosative stress. 
4.2. Future directions  
According to the main purpose of the present study, a major limitation of this study is the 
fact that real biological samples from both healthy volunteers and patients with different 
pathologies were not tested for our developed protocol. Therefore, it is pivotal in a near 
future to perform such analysis. If successful, the applicability of this method may be further 
evaluated, for instance, in the treatment monitoring of pathologies involving increased 
nitrosative stress state (e.g., CAD, neurodegenerative diseases, among others). 
Regarding technical aspects, it would be interesting to assess the protein content of the 
biological samples tested in this study, thus the efficacy of the protocol for protein 
precipitation could be better assessed. Moreover, the performance of our method should be 
compared with the performance exhibited by other methods already described and validated. 
For instance, the samples used in the present study could be tested using commercially 
available ELISA kits for 3-NT quantification. 
Moreover, it would be important to develop fast and easy protocols for sample concentration 
in order to obtain a more accurate quantification. Additionally, and given the current 
importance of the use of ecological methods, it would be interesting to find out whether more 
environment-friendly solvents, also called green solvents, could replace methanol in our 
developed method. Regarding this, ionic liquids might be a suitable alternative (Polyakova, 
Koo, & Row, 2006).  
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